Gene regulation of snake venom prothrombin activators by KWONG SHIYANG
  
 
GENE REGULATION OF  














A THESIS SUBMITTED FOR THE DEGREE 




DEPARTMENT OF BIOLOGICAL SCIENCES, 






 The writing of this section is a time which all PhD students look forward 
to. This time of reflection causes me to recall all the individuals who have guided 
and encouraged me along the way. Without their support, this journey would be 
more difficult. Hence, I would like to take this opportunity to express my heartfelt 
gratitude to these people. 
 
 I would like to thank my supervisor, Professor R. Manjunatha Kini for his 
guidance and support. Without his acceptance into the Protein Science Laboratory, 
this thesis would not have materialized. Prof Kini has always been an open 
channel of communication which is a luxury for any graduate student. His door is 
always open and he would be behind the desk ready for discussion. He has not 
only taught me to do high quality research, but more importantly, guided me to 
think critically and independently as an individual. I am also fortunate to have 
Associate Professor Ge Ruowen as my co-supervisor. Her guidance and input has 
been invaluable towards this PhD thesis. I would like to thank the graduate 
programme run by the National University of Singapore for their financial support. 
  
I was privileged to perform part of my research in Adelaide, Australia. I 
would like to thank Professor Anthony Woods of the University of South 
Australia for accepting me into his laboratory during that time. I would also like 
to thank Mr Peter Mirtschin of Venom Supplies Pty Ltd. for providing the snakes 
 ii 
to be sacrificed for their venom glands. The one month period in Australia was 
definitely a memorable experience for me.  
 
The Protein Science Laboratory is like a big extended family. I have made 
many friends and it has certainly enriched my experience. Firstly, I would like to 
thank my senior, Reza, who was my mentor when I was doing my honors project. 
Reza imparted many molecular biology techniques which he had painstakingly 
learnt by himself. I would like to thank our previous postdoctoral fellow, Robin, 
and my senior, Cho Yeow, for sharing their experiences with me. Research is 
stressful and it is great to have friends whom you can joke around with. I would 
like to give special mention to my lunch and coffee buddies: Amrita, Girish, 
Angelina and Chun Shin. I also thank Ryan, Shifali, Bhaskar, Angie, Sindhuja 
and Nazir for their support and making the lab nice to place to work in. Besides 
my lab members, special mention has to be given to Bee Ling. She has been a 
great source of support as our lab officer in the lab.  
 
I am very blessed to have my family who has been there to support me. 
My wife, Delphene, and our firstborn, Samuel, has been a constant source of 
inspiration and motivation. They have been my harbor where I seek refuge when I 
feel like giving up. I would have definitely not made it without them. I also want 
to thank my parents who had always supported and encouraged me to do a PhD. I 
thank them for their nurturance, love and for bringing me up to be the man that I 
am today. Also, I like to thank them for helping to look after Samuel so that I can 
 iii 
concentrate on writing this thesis. Most importantly, I thank God for always 










   Acknowledgements i 
 
   Table of Contents iv 
 
   Summary vi 
 
   List of Figures ix 
 
   List of Tables xi 
 
   Abbreviations xii 
 
Chapter One  Introduction 1 
   A brief introduction to gene duplication, 
the recruitment of snake venom toxins 
from body proteins, and transcription; 
overview of prothrombin activators from 
snake venom; Aims and Scope 
  
 
Chapter Two  Characterization of trocarin D VERSE promoter 50 
The role of VERSE promoter in trocarin D 
expression; characterization of VERSE for 
its regulatory cis-elements in primary 
Pseudonaja textilis snake venom gland 
cells and mammalian cell lines 
 
 
Chapter Three Identification of silencer cis-element within  78 
trocarin D intron 1 insertion/deletion segments 
Characterization and confirmation of 
trocarin D intron 1 insertions/deletions 
using mammalian cell lines 
 
  
Chapter Four  Identification of trans-factors that interact with  106 
novel VERSE cis-elements 
   Purification and identification of the 
transcription factors from nuclear extracts 




Chapter Five  Conclusions and future prospects 134 
   Conclusion, limitations, implications  




Appendices  161 
List of publications, patents and conferences  
achieved during the course of this thesis 
 




Snake venom prothrombin activators are functional and structural 
homologues of blood coagulation factors. It is hypothesized that the venom 
prothrombin activators evolved from blood coagulation factors by gene 
duplication. The copy gene of the blood coagulation factor is genetically modified 
which causes changes to its expression pattern. The modified copy gene becomes 
differentially expressed than its ancestral gene to become a toxin gene, i.e. it 
expression becomes elevated and exclusive in the venom gland. This whole 
process is broadly termed as “venom recruitment”.  
 
Trocarin D, a group D venom prothrombin activator, resembles activated 
mammalian blood coagulation factor X (FXa). Both trocarin D and FXa activate 
prothrombin to thrombin by targeting the same cleavage sites and have identical 
domain architectures. Despite such similarities, trocarin D and FXa have different 
expression patterns which facilitate their respective functions. While FX functions 
as a haemostatic factor and has low level of liver-specific expression, trocarin D 
functions as a toxin and has high level of venom gland-specific expression. A 
snake FX-like (TrFX) cDNA sequence was determined from the liver of 
Tropidechis carinatus. Comparison of trocarin D and TrFX gene organizations 
confirmed that trocarin D was “recruited” from TrFX. Both genes have identical 
architectures and significant sequence identities, except for insertions/deletions in 
their promoter and intron 1 regions. Compared to TrFX, the trocarin D promoter 
has a 264 bp insertion termed as the Venom Recruitment/Switch Element 
 vii 
(VERSE). Compared to TrFX, the trocarin D intron 1 has three insertions and two 
deletions. These insertions/deletions in the promoter and intron 1 regions are 
hypothesized to facilitate the “venom recruitment” process of TrFX into the 
venom gland transcriptome for elevated and specific expression as a toxin. 
However, more importantly, these insertions/deletions are hypothesized to 
regulate the expression of trocarin D. Using trocarin D as a representative, this 
thesis aims to characterize the promoter and intron 1 insertion/deletion segments 
to investigate the gene regulation of snake venom prothrombin activators. 
 
The trocarin D VERSE promoter segment was characterized using 
luciferase assays in primary snake venom gland cells and mammalian cell lines. 
VERSE is capable of driving luciferase expression and its up-regulatory effect is 
comparable to the full trocarin D promoter. Hence, this indicates that VERSE is 
the main segment responsible for the trocarin D elevated expression in the venom 
gland. Subsequent characterization confirms the presence of TATA-, GATA- and 
Y-box cis-elements. Three other novel cis-elements (Sup, Up1 and Up2) were 
also identified and characterized. The transcription factor which interacts with the 
Sup cis-element was purified and identified as a class 6 POU transcription factor. 
Although expression of trocarin D is venom gland-specific, VERSE is still able to 
drive luciferase expression in mammalian cell lines. Hence, the trocarin D intron 




The insertion/deletion segments within the trocarin D intron 1 region were 
characterized using luciferase assays in mammalian cell lines. A scaffold matrix 
attachment region which was previously predicted using bioinformatics tools was 
found to be nonfunctional. The characterization of the trocarin D intron 1 
insertion 2 segment pinpoints a 26 bp segment as a silencer cis-element which 
probably functions to “turn off” trocarin D expression in other tissues. The results 
of this thesis have elucidated how trocarin D is regulated for its elevated and 
tissue-specific expression. Finally, it has significantly contributed towards our 
understanding of gene regulation of snake venom prothrombin activators. 
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Our laboratory has extensively characterized trocarin D, a group D snake 
venom prothrombin activator, from the venom of Tropidechis carinatus. It is 
found to be functionally and structurally similar to activated mammalian factor X 
(FXa). A snake FX-like (TrFX) cDNA sequence was determined from the liver of 
Tropidechis carinatus. Trocarin D and TrFX share a high degree of similarity but 
are different enough to indicate that they are encoded by two different genes. 
Real-time polymerase chain reactions confirm that differences in expression 
patterns. Trocarin D is expressed exclusively in the venom gland at high levels 
compared to TrFX which is expressed mainly in the liver at lower levels. Their 
gene organizations were determined to investigate the genetic causes which result 
in this difference in expression patterns. Regions of differences were identified 
between the trocarin D and TrFX gene which are hypothesized to be responsible 
for the differences in gene regulation. These previous results suggest that trocarin 
D has evolved from TrFX by gene duplication. The TrFX copy gene underwent 
genetic modifications to gain venom toxin expression patterns which facilitated its 
differential expression in the venom gland. This whole process is broadly termed 
as “venom recruitment”. These genetic differences highlighted between trocarin D 
and TrFX give us an opportunity to characterize them for their regulatory 
properties, and therefore, understand the gene regulation of snake venom 
prothrombin activators. 
 
This recruitment of trocarin D from TrFX is one of the many instances 
which snake venom toxins have evolved from ancestral body proteins by gene 
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duplication. Before going into the details of this thesis, this chapter will introduce 
the phenomenon of gene duplication and the characteristics of ancestral body 
proteins which are favored for “venom recruitment”. During this “recruitment” 
process, changes occur within the regulatory regions of the duplicated gene which 
influences its transcription regulation, and hence, alter its expression patterns. 
Therefore, this chapter will also briefly describe the process of transcription and 
its regulation. As this thesis focuses on investigating the “recruitment” of snake 
venom prothrombin activators from blood coagulation factor proteins, this chapter 
will also discuss the work that our laboratory has previously done to establish the 
evolutionary relationship between these two groups of proteins. Finally, this 
chapter will discuss the factors that motivate the aims and scope of this thesis. 
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GENE DUPLICATION 
One of the earliest observations of gene duplication was the doubling of a 
chromosomal band in a mutant fruit fly Drosophila melanogaster which resulted 
in a reduction in eye size (Bridges 1936). As more genomes get sequenced and 
annotated, the phenomenon of gene duplication is becoming more evident during 
the evolution and development of genomes. The most obvious contribution of 
gene duplication is the production of new genetic material for evolution to modify 
and generate new genes with new functions. This allows an organism to 
constantly adapt and survive when changes occur in its environment. The human 
genome has about 40 000 genes, out of which approximately 38% of them are 
duplicated genes (Li et al. 2001b). For example, one of the largest multigene 
families in the human genome which  has arisen due to gene duplication are the 
functional olfactory receptor (OR) genes (Niimura and Nei 2003). 
 
Generation of Duplicated Genes 
There are three scenarios in which gene duplication can occur, namely (1) 
unequal crossing over, (2) retroposition and (3) chromosomal duplication. In the 
event of unequal crossing over, the duplicated and original regions are often 
located in tandem, i.e. both duplicated and original genes are linked together on 
the same chromosome. Depending on the position of the crossing over, the 
duplicated region can be part of a gene, an entire gene or even multiple genes. 
The duplicated region will have the same gene structures as that of the original 
region, i.e. promoter, exon and intron regions. In the event of retroposition, a 
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messenger RNA (mRNA) is retrotranscribed into a complementary DNA (cDNA) 
and randomly inserted into the genome. Hence, unlike that of the unequal crossing 
over, the position of duplicated region is often unlinked with the original gene. 
Also, as the inserted segment is a complementary mRNA strand, the duplicated 
region usually has no gene structure, i.e. there are no promoter and intron regions, 
and might have a poly T region. In the event of a chromosomal duplication, gene 
duplication occurs probably due to a lack of disjunction among daughter 
chromosomes after DNA replication. However, this often occurs in the plant 
genomes and seldom in the animal genome (LI Wen-Hsiung 1997). 
 
Fate of the Duplicated Gene 
The birth-and-death model of evolution assumes that new genes are 
constantly being created by gene duplication, and while some of the duplication 
genes get incorporated and maintained in the genome, the rest of them end up 
being deleted due to a strong purifying selection pressure (Nei et al. 1997; Nei et 
al. 2000). For those duplicated genes that are maintained in the genome, they end 
up either (1) being a pseudogene (pseudogenization), (2) conserving the parental 
function, (3) retaining part of the parental function (subfunctionalization) or (4) 
gaining a novel function (neofunctionalization). 
 
Pseudogenization 
When a gene is duplicated by retrotransposition, there is a loss of 
regulatory elements in the duplicated gene, i.e. no promoter and intron regions. 
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Therefore, transcription cannot be initiated and the duplicated gene ends up being 
a pseudogene. However, in certain situations, the insertion can occur downstream 
a promoter region. In this case, the duplicated gene could end up being 
transcribed and expressed (Long 2001). Pseudogenization can also occur when 
the duplicated gene is initially fixed in the genome but later becomes 
nonfunctional or unexpressed due to mutations, which affect its function or 
structure. 
 
Pseudogenes can be found in approximately half of all mammalian protein 
families with the greatest representation found in housekeeping and ribosomal 
families of genes (Zhang and Gerstein 2004). A good example of this process can 
be observed in the human olfactory receptor gene family which more than 60% of 
the genes are pseudogenes (Rouquier et al. 2000). This could be an outcome of a 
relaxation in the olfactory receptor functional constraint. This relaxation could be 
due to the development of other sensory mechanisms, such as better vision, which 
compensate for a less developed olfactory system. 
 
Conservation of Gene Function 
Occasionally, it is beneficial for the organism to have duplicated 
functional copies of a gene as it allows more amounts of the protein or RNA to be 
produced. In this case, strong selection pressure prevents mutations from 
modifying the gene function of the duplicated gene. Translational RNAs such as 
tRNA, rRNA, and histones are usually encoded by multiple gene copies that have 
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arisen by gene duplication (Duret 2000; LI Wen-Hsiung 1997; Stevenson and 
Schmidt 2004; Tsunemoto and Matsuo 2001). There are four histone genes (H1, 
H2A, H2B and H4) present in Drosophila simulans which form a gene cluster 
(Tsunemoto and Matsuo 2001). Evidence of gene duplication lie in the similarity 
of the gene sequences which only differ by 6.3%.  
 
Subfunctionalization 
Unless it is beneficial for extra copies of the gene to be present (as 
discussed above), it is unlikely for a genome to stably maintain two genes with 
identical functions as it would be redundant and costly (Nowak et al. 1997). 
Therefore, in the event of subfunctionalization, to ensure that both genes are kept 
under selective pressure and are able to be fixed into the genome, there is a 
partitioning of the parent gene function. The duplicated gene usually adopts an 
aspect of the parent gene function (Hughes 1994), and/or alter their expression 
patterns (Gu et al. 2002), i.e. if the ancestral gene is expressed in tissues A and B, 
modifications in the cis-regulatory regions would result in one duplicate gene to 
be expressed in tissue A and the other to be expressed in tissue B.  
 
An example of subfunctionalization, whereby there is a change in 
expression patterns,  is snake venom prothrombin activator, trocarin D, and its 
blood coagulation factor X (FX) counterpart (Reza et al. 2005a). Both of these 
genes promote blood coagulation by activating prothrombin. However, trocarin D 
is expressed only in the venom glands while the FX counterpart is expressed in 
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the liver. An example of subfunctionalization, whereby the duplicated gene 
specializes in an aspect of the parent gene functions, can be observed in the 
duplicated pancreatic ribonuclease gene of the leaf-eating monkey Pygathrix 
nemaeus. Compared to the parent gene, the duplicated gene has evolved to have 
an enhanced ribonucleolytic activity while losing the ability to degrade double-
stranded RNA (Yu et al. 2010). 
 
Neofunctionalization 
The most important outcome of gene duplication is the creation of new 
novel gene functions. During neofunctionalization, the duplicated gene which is 
free from selection pressure gains mutations which alter its gene function. The 
duplicated gene evolves either a new function, or in most cases, one which is 
related to that of its parent.  
 
An example of neofunctionalization can be seen in the three-finger toxin 
(3FTX) multigene family. The members of this family have evolved by gene 
duplication and their structure-function relationships have been well-characterized 
(Kini 2002). Structurally, all the members of this family share a common structure 
of three beta-stranded loops extending from a central core. Despite the structural 
similarities, the members are functionally very diverse. Their functions range 
from being a neurotoxin, cardiotoxin, acetylcholinesterase inhibitor and many 
others (Kini 2002). This diversification is due to molecular mutations within the 
functional sites which often result in new ligand-binding specificities (Kini 2002). 
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RECRUITMENT OF SNAKE VENOM TOXINS FROM BODY PROTEINS 
Snake venom is a complex mixture of biologically active molecules which 
perform a variety of functions which ranges from immobilizing, paralyzing, 
killing and digesting their prey organisms. Interestingly, many of these toxin 
proteins have been observed to be structurally and functionally related to body 
proteins (Fry 2005). Hence, it is hypothesized that venom proteins originate from 
body proteins whose genes have been “recruited” into the venom gland 
transcriptome by gene duplication. One of the first observations of “venom 
recruitment” by gene duplication was that 3FTX venom proteins had evolved and 
diversified from a single ribonuclease ancestor (Strydom 1973). This 
“recruitment” process has not only been observed in snakes but also in venoms of 
various others animals, such as cone snails, scorpions and sea anemones. 
However, this thesis will use snake venom toxins as a focal point to illustrate how 
body proteins have been recruited into the venom arsenal. 
 
Characteristics of Body Proteins that are Recruited for Venom Arsenal 
From the characteristics of the venom toxin proteins and their related body 
proteins, general properties which make a body protein favorable for 
“recruitment” into the venom toxin arsenal can be characterized.  
 
Structural Characteristics 
The presence of an N-terminal signal peptide and a large proportion of 
cysteine residues are two structural characteristics that favors a body protein for 
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recruitment. Snake venom proteins are secreted out of the venom gland upon 
expression. Therefore, the presence of an N-terminal signal peptide in the 
ancestral body protein would be favorable. However, a non-secretory body 
protein could also be recruited but it will need to undergo the incorporation of a 
signal peptide by either exon shuffling or interlocus gene conversion and 
retrotransposition (Patthy 2003).  
 
Mutations are one of the main driving forces for functional diversification 
in snake venom toxins. Therefore, it is important for the venom toxins to be 
structurally stable so that they can retain mutations without resulting in any fatal 
structural changes. Cysteine residues form disulfide bonds which confer structural 
stability. Hence, body proteins with large proportion of cysteine residues are 
favorable for recruitment.  
 
Functional Characteristics 
As snakes feed on a wide range of organisms, it would be advantageous 
for their venom to be functional in all of their preys. Therefore, body proteins 
which either target substrates which are universally present or have bioactivities 
that are widely conserved across the Kingdom Animalia are favorable for 
recruitment into the venom gland transcriptome. An example of a universally 
present substrate is hyaluronic acid which is throughout connective, epithelial, 
and neural tissues. Hyaluronidase hydrolyzes this substrate at the 1-4 linkages 
between N-acetyl-β-D-glucosamine and D-glucuronate residues. Hyaluronidase 
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can be found in the venom of Agkistrodon acutus (Xu et al. 1982). Upon 
envenomation, this venom toxin causes the degradation of the tissues which leads 
to an increase in tissue permeability, and hence, enhances efficient spreading of 
the venom. 
 
If a venom protein resembles a body protein whose bioactivity is widely 
conserved, the venom protein can attack the prey’s system by functioning as an 
exogenous substitute for the endogenous protein. The venom protein then elicits 
its toxic effect by causing a physiological imbalance or disrupting a physiological 
response. In the case of a physiological imbalance, the concentration of venom 
protein together with the endogenous protein will resemble an overexpression of 
the endogenous protein. As a body system is tightly controlled by regulating the 
concentration of the involved proteins, a sudden unwanted increase in protein 
concentration will result in undesired responses or even be fatal. One example is 
the AVIT venom toxin whose ancestral protein is the prokinectin protein (Fry 
2005). Upon envenomation, the AVIT toxins act as potent agonists of mammalian 
prokineticin receptors, and their binding mimics the effect of an endogenous 
prokineticin overdose. AVIT toxins have been shown to cause in vitro intestinal 
cramping and in vivo increased sensitivity to pain (Li et al. 2001a; Mollay et al. 
1999; Schweitz et al. 1999). In the case of a disruption in physiological response, 
the venom protein targets the same receptors as the endogenous protein. Hence, 
the venom protein functions as a competitive inhibitor to prevent the endogenous 
protein from binding to its receptor. One example of a venom inhibitor is 
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erabutoxin b, an α-neurotoxin which belongs to the 3FTX family from Laticauda 
semifasciata (Sato and Tamiya 1971). This neurotoxin causes paralysis by 
competing against and preventing endogenous neurotransmitters such as 
acetylcholine from binding to the nicotinic acetylcholine receptor. 
 
Body Proteins to Venom Toxins: Changes in Expression Pattern 
For a body protein to be recruited into the venom gland transcriptome, one 
of the major modifications it must undergo is changes in expression pattern, i.e. 
expression levels and tissue-specific expression. Unlike the expression pattern of 
the body proteins which is usually constitutive and low, the expression of the 
venom toxins are inducible and high. The expression of the venom toxins has to 
be inducible as the toxins need to be expressed only when the glands are empty 
and stopped when the glands are full. Also, as the venom is usually an important 
component of the snake’s defense and offense, the venom toxins need to be 
replenished quickly when the venom gland is emptied (Paine et al. 1992; 
Rotenberg et al. 1971). The venom toxins have elevated levels of expression so 
that the toxins would be present in sufficient concentrations within the venom to 
bring about their toxic effects. Besides these, as the venom toxins could be 
potentially toxic to the snake itself, one of the preventive measures is for the 
venom toxins to be exclusively expressed in the venom glands. For these changes 
of expression pattern to occur, there must be modifications to the regulatory cis-
elements of the gene.  
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Previous studies have focused on documenting the evolutionary 
relationships between the venom toxin proteins and their ancestral parent protein 
by using phylogenetic analysis and comparing the gene sequences. However, little 
focus has been given to investigate and verify how these genetic differences 
actually bring about changes in expression pattern. Therefore, it would be 
interesting to advance this field of toxicology to its next level by investigating this 
area. Transcription and its regulation play important roles in controlling 
expression levels and tissue specific expression. The next section will briefly 
describe the process of transcription and the mechanisms which regulate it. 
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TRANSCRIPTION IN EUKARYOTES AND ITS REGULATION 
Transcription and translation are two crucial processes for a eukaryotic 
cell to get instructions for its survival and function from its genetic material. 
During transcription, genetic material DNA is copied into a complementary RNA 
nucleotide sequence within the nucleus. This RNA sequence is further processed 
and matured in mRNA. After maturation, the mRNA is then exported out of the 
nucleus into the cytoplasm. During translation, based on the information that is 
encoded by the mRNA, proteins are synthesized and folded in the cytoplasm. 
Protein expression is tightly regulated from the transcriptional to post-
translational stages to prevent unwanted protein synthesis. If unregulated or 
incorrect protein synthesis occurs, the cell will not be able to function correctly 




RNA polymerase II reads the DNA and synthesizes a RNA copy. 
However, this polymerase is unable to recognize the promoter sequence of a gene 
alone. Transcription factors aid the polymerase to bind at the correct transcription 
start site and help to prepare the DNA for transcription by denaturing the double-
stranded DNA. Each transcription factor binds to specific nucleotide sequences 
called cis-elements and each gene has its own specific collection of cis-elements. 
When conditions within a cell require a gene to be expressed, transcription is 
initiated by gathering the necessary transcription factors and polymerase on its 
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promoter region. This assembly of proteins is called the transcription initiation 
complex. However, this does not guarantee transcription success. It has been 
shown in vivo that there is a high tendency for the transcription initiation complex 
to be released just after it exits the promoter, and this result in truncated 
transcripts of about 2 to 15 nucleotides long. This release is due to the instability 
of the transcription initiation complex and this process is termed abortive 
initiation  (Goldman et al. 2009; Hsu 2002). For transcription initiation to be 
successful, the transcription initiation complex has to become more stable by 
undergoing certain adjustments in its protein-protein and protein-DNA 
interactions (Dvir 2002).  
 
Transcription Elongation 
The RNA polymerase II uses one of the DNA strand as the template strand. 
As it transverses the DNA strand in the 3’ to 5’ direction, it synthesizes a RNA 
copy in the 5’ to 3’ direction through nucleotide base pairing complementary to 
the DNA template strand (Spencer and Groudine 1990). Multiple RNA 
polymerase II can bind to the DNA template strand simultaneously. Resulting in 
multiple RNA strands to be rapidly produced from a single gene. During this 
stage, proofreading mechanism also takes place to replace any mis-paired 
nucleotides (Donahue et al. 1994; Komissarova and Kashlev 1997; Toulme et al. 
1999; Wang et al. 2009).  
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Transcription Termination 
Unlike transcription termination in prokaryotes, termination in eukaryotes 
involves two multisubunit proteins called cleavage stimulation factor F, and 
cleavage and polyadenylation specific factor (Bruce Alberts et al. 1994). These 
two proteins are associated with the RNA polymerase II and travel together 
during transcription. Once the polymerase reaches and transcribes the termination 
signal of a gene, the two proteins are transferred to the transcribed RNA. 
Additional proteins are then attracted and the formation of the 3’ mRNA end is 
initiated. The mRNA is first cleaved which forms the 3’ end. An enzyme called 
the poly-A polymerase then adds approximately 200 adenosine (A) nucleotides 
(one at a time) to this 3’ RNA end. This poly-A polymerase does not require a 
template; hence, the poly-A tail of an mRNA is not genetic coded. Poly-A binding 
proteins then assemble onto the poly-A tail and determine the length of the 
mRNA poly-A tail. These poly-A binding proteins remains attached to the mRNA 




Although the same set of genes is present in all the cells of an organism, 
not all the genes are expressed. Each individual cell expresses a distinct subset of 
genes and one main mechanism that determines this is transcription regulation. 
During this process, the cis-elements of a gene and their corresponding 
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transcription factors are the determining factors which regulate if and when a gene 
is transcribed, and how much RNA is produced.  
 
Transcription factors 
There are different groups of transcription factors that have different 
properties with regards to regulating transcription. (1) General or basal 
transcription factors (such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) 
which form the preinitiation complex. This complex functions to position the 
RNA polymerase II over the transcription start site and assist in transcription 
initiation by denaturing the DNA (Lee and Young 2000; Orphanides et al. 1996). 
(2) Activating transcription factors which “turn on” genes by promoting 
transcription. They recruit the general transcription factors to the promoter, 
thereby promoting transcription (Choudhuri 2004). (3) Silencing transcription 
factors which “turn off” genes by deterring transcription. Some of these factors 
inhibit transcription by preventing the assembly of general transcription factors 
(Choudhuri 2004).  
 
The availability of these transcription factors also plays a role in 
transcription regulation. If a gene is to be suppressed, expression of silencing 
transcription factors may get elevated and/or the activating transcription factors 
may get sequestered. Vice versa, if a gene is to be expressed, the expression of the 
activating transcription factors may get elevated and/or the silencing transcription 
factors may get sequestered.  
Chapter I - Introduction 
18 
Regulatory cis-elements 
The cis-elements determine which transcription factors are attracted to the 
regulatory regions of the gene. Each transcription factor brings along its influence 
on the transcription initiation complex, i.e. some promote transcription by 
increasing the stability the complex and some deter transcription by destabilizing 
the complex. Whether a gene gets eventually transcribed depends on the overall 
influence of the transcription factors. These cis-elements reside in the non-coding 
regions of a gene, i.e. from the promoter (or further upstream) to the translational 
start site, intron regions, and from the stop codon to the 3’ end of the gene 
(untranslated or untranscribed regions). Enhancers are also cis-elements which are 
located upstream or downstream of a gene. Some enhancers are not necessarily 
near the gene it acts on and can be even found on another chromosome 
(Spilianakis et al. 2005). Although these enhancers may be far from the gene of 
interest, the ability of the DNA to fold and coil allows these enhancers to be 
brought geometrically near to the initiation complex to elicit its effect. 
 
Similar to the transcription factors, the steric availability of the cis-
elements also plays a role in transcription regulation. The folding of the gene 
within a chromosome may cause its cis-elements to be made sterically unavailable. 
When a gene is to be expressed, the chromosome may unfold and expose the 
regulatory cis-elements. Hence, transcription factors are able to interact with the 
cis-elements and promote transcription initiation. 
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RECRUITMENT OF BLOOD COAGULATION FACTORS  
INTO THE VENOM TO FUNCTION AS TOXINS 
 
One group of venom proteins that have been recruited from body proteins 
by gene duplication are the group C and D prothrombin activators whose ancestral 
proteins are blood coagulation factor proteins. This thesis aims to investigate how 
the genetic differences have enabled the blood coagulation factors to change their 
expression levels and tissue specific expression so that they can function as 
venom toxins. This section aims to describe how the evolutionary relationship 
between these two groups of proteins was established. 
 
Group C and D Prothrombin Activators 
Snake venoms comprise of a wide range of toxins that target two major 
systems, namely the neuromuscular and the haemostatic system. The proteins 
targeting the haemostatic system include procoagulants, anticoagulants, 
fibrinolytic components, agonists and antagonists of platelet aggregation, and 
hemorrhagic proteins (Braud et al. 2000; Chow and Kini 2001; Hutton and 
Warrell 1993; Kini 2004; Kini and Chow 2001; Kini and Evans 1990; Markland 
1997; Markland 1998; Morita 2004). Procoagulant proteins promote blood 
coagulation and in general are proteinases which activate specific blood 
coagulation factors (Davie 2003). Prothrombin activators are procoagulant 
proteins that specifically activate prothrombin and induce coagulation. A wide 
range of prothrombin activators from snake venoms have been identified and 
characterized (Gao et al. 2002; Hasson et al. 2003; Joseph and Kini 2001; 
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Kornalik and Blomback 1975; Morita and Iwanaga 1978; Rosing and Tans 1991; 
Rosing and Tans 1992; Schieck et al. 1972; Silva et al. 2003; Speijer et al. 1986; 
St Pierre et al. 2005; Yamada and Morita 1997). This group of proteins differs in 
their structure, cofactor requirements and end-products formed. Based on these 
differences, snake venom prothrombin activators are classified into four groups 
(Kini et al. 2001) (Table 1.1). Group A and B prothrombin activators, such as 
ecarin from Echis carinatus venom (Kornalik and Blomback 1975; Morita and 
Iwanaga 1978; Nishida et al. 1995; Schieck et al. 1972) and multactivase from E. 
multisquamatus venom (Yamada and Morita 1997) respectively, are 
metalloproteinases and convert prothrombin to meizothrombin. Group C and D 
prothrombin activators, such as oscutarin from Oxyranus scutellatus venom 
(Owen and Jackson 1973; Speijer et al. 1986; Walker et al. 1980; Welton and 
Burnell 2005) and notecarin from Notechis scutatus scutatus venom (Tans et al. 
1985) respectively, are serine proteinases and convert prothrombin to thrombin. 
 
Our laboratory extensively characterized one representative each of group 
C (pseutarin C) and group D (trocarin D) prothrombin activators, and showed that 
they are very similar to blood coagulation factors. Therefore, it was postulated 
that these venom prothrombin activators have evolved from blood coagulation 
factors by gene duplication and accelerated evolution. 
 




 Table 1.1: Classification of snake venom prothrombin activators. 










A None Metalloproteinase Meizothrombin ~47 kDa None Ecarin  
B Ca2+ Metalloproteinase Meizothrombin 
Two subunits 





phospholipids Serine proteinase Thrombin 
Two subunits 









plus factor Va 
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Venom Prothrombin Activators and Mammalian Blood coagulation Factors 
are Structurally and Functionally Similar 
 
Group C and D prothrombin activators are serine proteinases, which show 
functional similarities in their cofactor requirements and products produced to 
endogenous prothrombin activators such as factor Xa (FXa) (Table 1.1). The 
structures of group C and D procoagulant proteins were determined to get a 
detailed understanding of the structure-function relationships of not only snake 
venom prothrombin activators, but also that of mammalian blood coagulation 
factors. The size of group D prothrombin activators was smaller and their 
quaternary structure was simpler than group C prothrombin activators, trocarin D 
from Tropidechis carinatus venom was characterized as a representative of group 
D prothrombin activators (Joseph et al. 1999; Joseph and Kini 2004; Rao et al. 
2003a). Subsequently, pseutarin C from Pseudonaja textilis venom was 
characterized as an example of group C prothrombin activators (Rao et al. 2003b; 
Rao et al. 2004; Rao and Kini 2002).  
 
Group D Prothrombin Activators (Trocarin D) 
The first member of this group, notecarin, was isolated and characterized 
by Rosing and his coworkers from Notechis scutatus scutatus venom (Tans et al. 
1985). Since then, similar prothrombin activators have been characterized from 
several other snake venoms. Group D prothrombin activators are glycoproteins 
with a molecular weight of ~50 kDa (Table 1.1). They are found exclusively in 
Australian elapid snakes (Rosing and Tans 1991). They share striking 
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resemblance and requirements for optimal activity with blood coagulation FXa 
(Table 1) (Joseph et al. 1999; Marsh et al. 1997; Rao and Kini 2002; Stocker et al. 
1994; Tans et al. 1985).  
 
Tropidechis carinatus snake venom was first documented to have 
procoagulant properties 26 years ago (Chester and Crawford 1982). A 
prothrombin activator was isolated using gel filtration and benzamidine-based 
affinity chromatography, and was partially characterized (Marsh et al. 1997). 
Since then, trocarin D, a prothrombin activator, was purified from T. carinatus 
venom to homogeneity using gel filtration, anion-exchange chromatography, and 
reverse-phase high performance liquid chromatography (RP-HPLC) (Joseph et al. 
1999). This purification procedure was refined to a single-step RP-HPLC method 
and was used for the purification of other group D prothrombin activators such as 
notanarin D from N. ater niger venom, notecarin D from N. scutatus venom and 
hopsarin D from Hoplocephalus stephensi venom (Rao et al. 2003a).  
 
The functional characterization of trocarin D indicated that its properties 
were similar to that of mammalian blood coagulation FXa. Both these proteins 
promote blood coagulation by activating prothrombin to thrombin (Joseph et al. 
1999). Also, the cleavage products of bovine prothrombin produced by trocarin D 
activation were identical to that of human FXa; both trocarin D and FXa activate 
prothrombin by targeting the same two cleavage sites (Arg274-Thr275 and Arg323-
Ile324) (Joseph et al. 1999). Further studies showed that trocarin D, like 
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mammalian FXa,  requires all three cofactors, Ca2+ ions, phospholipids and 
activated factor V (FVa), for its optimal activity (Joseph et al. 1999). A 
comparison of the protein yield in their respective tissues revealed that trocarin D 
is expressed ~1,150 times higher in the venom gland than FX in the liver (Joseph 
et al. 1999; Reza et al. 2005a). Similar to other prothrombin activators (Masci et 
al. 1988; Rao et al. 2003a), trocarin D is used as a toxin in prey capture, and it 
induces cyanation and death in experimental animals (Joseph et al. 1999) through 
disseminated intravascular coagulopathy. On the other hand, mammalian FXa 
functions as a haemostatic protein to prevent excessive blood loss during a 
vascular injury. Trocarin D and mammalian FXa are catalytically similar, despite 
having different physiological roles. This led to the structural study of trocarin D 
to examine its molecular characteristics and determine whether it is similar to 
mammalian FXa or a structurally different protein with similar functions to 
mammalian FXa. 
 
Trocarin D is a two chain protein. The complete amino acid sequences of 
light and heavy chains was determined via Edman degradation (Joseph et al. 
1999). Structural comparison against mammalian FXa revealed that trocarin D 
has identical domain structure and significant sequence identity (~53-60%) (Fig. 
1.1) (Joseph et al. 1999; Rao et al. 2003a). Similar to FXa, its light chain (141 
residues) contains a Gla domain with 11 γ-carboxylated glutamic acid (Glu) 
residues which is followed by two epidermal-growth factor-like domains (EGF-I 
and EGF-II). Its heavy chain (235 residues) contains the serine proteinase domain 
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with the characteristic catalytic triad (His42, Asp88 and Ser185).  These two chains 
are held together by a single inter-chain disulfide bond. The main differences 
between trocarin D and FXa structure are in their posttranslational modifications 
(Fig. 1.1). (1) Trocarin D is glycosylated but mammalian FXa is not. Trocarin D 
contains O-linked carbohydrate at Ser52 of the light chain and N-linked 
carbohydrate at Asn45 of the heavy chain (Joseph et al. 1999). Interestingly, O-
linked carbohydrate moiety has N-acetylglucosamine, which is found commonly 
in nuclear and cytoplasmic proteins but rarely in secreted proteins (Hanover et al. 
1987; Holt et al. 1987; Holt and Hart 1986; Snow et al. 1987). It is hypothesized 
that these glycosylations may help to protect trocarin D from proteolysis and 
confer it thermal stability (Rao et al. 2003a; Wang et al. 1996). In contrast, 
although human FX contains two O-glycosylation and two N-glycosylation 
moieties (Inoue and Morita 1993), all the carbohydrates moieties are present 
exclusively on the activation peptide and they are removed when FX is activated. 
Hence, mammalian FXa is not glycosylated. (2) While Asp63 of FX light chain 
EGF-I domain is β-hydroxylated (McMullen et al. 1983; Stenflo et al. 1987), the 
corresponding residue in trocarin D is not (Joseph et al. 1999).  
 
Despite these differences in the posttranslational modifications, all the 
structural properties of trocarin D are identical to that of mammalian FXa. 
Similarly, other group D prothrombin activators, such as hopsarin D (Rao et al. 
2003a), are functional and structural homologues of mammalian FXa. 
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Figure 1.1: Domain architecture of mammalian FXa, trocarin D and 
pseutarin C catalytic subunit (PCCS). The “Y” represent Gla residues; solid 
diamond represents β-hydroxylation; open triangles represent O-linked 
carbohydrate at Ser52; solid triangles represent N-linked carbohydrate at Asn45. 
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Group C Prothrombin Activators (Pseutarin C) 
The first member of this group, oscutarin, was isolated and characterized 
from Oxyranus scutellatus venom (Owen and Jackson 1973; Speijer et al. 1986; 
Walker et al. 1980; Welton and Burnell 2005). Group C prothrombin activators 
are made up of two subunits with a total size of ~300 kDa (Table 1.1). Like group 
D prothrombin activators, they are found exclusively in Australian elapid snakes 
(Rosing and Tans 1991). They have striking resemblance and co-factor 
requirements as the blood coagulation “FXa-FVa” complex (Table 1.1) 
(Filippovich et al. 2005; Masci et al. 1988; Rao and Kini 2002; Speijer et al. 1986; 
Walker et al. 1980). 
 
Pseutarin C was purified from P. textilis venom using gel filtration 
followed by hydroxyapatite chromatography (Rao and Kini 2002). Initial studies 
indicate that pseutarin C activates prothrombin to thrombin, and requires only 
Ca2+ ions and phospholipids for its optimal activity (Rao and Kini 2002). These 
characteristics are similar to that of the mammalian “FXa-FVa” complex. 
Pseutarin C is a complex of two subunits and they were separated under 
denaturing conditions of RP-HPLC (Rao and Kini 2002). These subunits were 
~60 kDa and ~220 kDa in size. The smaller subunit had serine proteinase activity, 
and hence was termed as the pseutarin C catalytic subunit (PCCS). The larger 
subunit was termed as the pseutarin C nonenzymatic subunit (PCNS). A 
comparison of the protein yield in their respective tissues revealed that pseutarin 
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C is expressed ~4,200 times higher in the venom gland than the amount of blood 
factors and zymogens in the liver (Rao and Kini 2002). 
 
Pseutarin C catalytic subunit (PCCS)  
Functional studies revealed that PCCS has similar activities and co-factor 
requirements to mammalian FXa and group D prothrombin activators (Rao and 
Kini 2002). In isolation, PCCS has low prothrombin activating abilities which is 
enhanced in the presence of FVa (Rao and Kini 2002). The amino acid sequence 
of PCCS was determined using Edman degradation and cDNA sequencing (Rao 
et al. 2004; Rao and Kini 2002). The deduced amino acid sequence showed ~42% 
identity to mammalian FX and 74-83% identity to group D prothrombin activators 
(Rao et al. 2004). The domain architecture of PCCS is identical to mammalian FX 
and group D prothrombin activators (Fig. 1.1). PCCS is made up of a light and a 
heavy chain which are held together by a single interchain disulfide bond (Rao et 
al. 2004). The light chain has a Gla domain, which has 11 γ-carboxylated Glu 
residues, followed by two EGF-like domains, and the heavy chain contains a 
serine proteinase domain (Fig. 1.1) (Rao et al. 2004). Based on these overall 
functional and structural results, PCCS is a homologue to FXa and group D 
prothrombin activators. However, PCCS differs from FX in the size of its 
activation peptide and posttranslational modifications (Rao et al. 2004). Firstly, 
the activation peptide of PCCS (27 residues) is significantly shorter than the 
highly variable mammalian FX (48-52 residues) (Rao et al. 2004). The activation 
peptide is cleaved off once PCCS is activated, and hence does not play a role in 
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its final protein function. It is interesting that, while the size of segments which 
are essential for the final protein function is conserved, segments that are not 
necessary for its final function is reduced in size (Rao et al. 2004). Similar size 
reduction of nonessential segments is also present in PCNS where it has a smaller 
domain B size compared to that of mammalian FV (discussed below). Secondly, 
the Ser52 and Asn45 residues of the PCCS light and heavy chains are O- and N-
glycosylated respectively. These residues are also O- and N-glycosylated 
respectively in trocarin D but not mammalian FXa. 
 
FXa is activates FV to FVa (Thorelli et al. 1998) and helps to shield FVa 
from APC inactivation through their interaction (Nesheim et al. 1982). PCCS 
forms a constant and stable complex with PCNS in the venom (Rao et al. 2003b; 
Rao et al. 2004). Hence, besides activating prothrombin, PCCS (FXa-like) may 
also function in the venom as a catalyst for activation of PCNS in the venom 
(FVa-like) and help to protect it against APC inactivation in the prey’s body (Rao 
et al. 2003b). Thus, PCCS is a functional and structural homologue of mammalian 
FXa. 
 
Pseutarin C nonenzymatic subunit (PCNS)  
The amino acid sequence of PCNS was determined using Edman 
degradation and cDNA sequencing (Rao et al. 2003b; Rao and Kini 2002). The 
deduced amino acid sequence of PCNS shows ~50% identity to mammalian FV 
and they have identical structural architecture (Fig. 1.2) (Rao et al. 2003b). PCNS 
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has five domains: A1, A2, B, A3, C1 and C2. Alignment of PCNS with FV of 
other species shows that functionally important domains A and C are highly 
conserved (Rao et al. 2003b). Thus, PCNS is a homologue of mammalian FV 
(Rao et al. 2003b).  




1 345 695 1564 1892 2051 
A1 A2 B A3 C1 C2 
A1 A2 A3 C1 C2
1 348 691 818 1145 1298 1461 
FV 
PCNS 
Figure 1.2: Domain architecture of mammalian FV and pseutarin C 
nonenzymatic subunit (PCNS). The potential N-glycosylation sites in bovine FV 
and PCNS are shown. Open circles represent potential novel N-glycosylation sites 
in PCNS compared with bovine FV. Solid circles represent potential N-
glycosylation sites that are conserved potential N-glycosylation sites in both 
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Despite the overall structural similarities, there are differences between 
PCNS and mammalian FV. Firstly, the size of domain B in PCNS is shorter (127 
residues) compared to that of fishes (fugu: 530 residues and zebrafish: 756 
residues) and mammals (mouse: 843 residues, bovine: 869 residues, and human: 
882 residues) (Rao et al. 2003b). It is observed that the size of domain B, which is 
nonessential in the active functional PCNS, is reduced (discussed above). During 
FV activation, domain B is released via proteolytic cleavages by thrombin or FXa 
at three activation sites, Arg709, Arg1018 and Arg1545 (bovine FV numbering) 
(Foster et al. 1983; Nesheim et al. 1979; Suzuki et al. 1982). Arg709 and Arg1545 
cleavage sites are conserved in PCNS but Arg1018 is not (Rao et al. 2003b). 
However, the presence of Arg709 and Arg1545 cleavage sites are sufficient for the 
complete removal of domain B. Besides these three cleavage sites, mammalian 
FV is also activated by FXa at two other cleavage sites, Arg348 and Arg1765 
(Thorelli et al. 1998). While the cleavage site at Arg348 is conserved in PCNS, the 
cleavage site at Arg1765 is not conserved in PCNS (Rao and Kini 2002). In 
addition to these conserved sites, the presence of another FXa proteolytic 
cleavage site at Arg346 in PCNS was determined (Rao and Kini 2002). In 
summary, although mammalian FV has more activation cleavage sites, the 
activation of PCNS and FV by the removal of domain B is similar. Secondly, 
there are differences in the posttranslational modifications such as N-
glycosylation, phosphorylation and sulfation of PCNS and mammalian FV (Rao 
et al. 2003b). (1) While bovine FV has 29 glycosylation sites, PCNS has only 11 
potential N-glycosylation sites (Fig. 2) (Rao et al. 2003b). 18 of the 29 N-
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glycosylation sites in bovine FV are found in domain B; hence, the size reduction 
of the PCNS domain B accounts for the significant difference in number of 
potential N-glycosylation sites. Two other potential PCNS N-glycosylation sites 
were determined by Edman degradation and were found to be not glycosylated. 
Subsequently, only three of the remaining nine potential PCNS N-glycosylation 
sites are conserved with those in bovine FV. The rest are novel potential N-
glycosylation sites. (2) Mammalian FV has a phosphoserine (Ser692) but PCNS 
does not (Rao et al. 2003b). (3)  There are six sulfation sites in human FV which 
are absent in PCNS (Rao et al. 2003b). It is speculated that sulfation may be 
important for regulating the activation of FV by thrombin (Pittman et al. 1994). 
However, in the case of pseutarin C, the nonenzymatic subunit may not be 
activated by thrombin, as such proteinases have not been found in P. textilis 
venom (Rao et al. 2003b). The constant and stable association with its active 
counterpart, PCCS, might be able to account for its activation (discussed above). 
 
PCNS possesses modifications or associations to enhance its function as a 
toxin. In the coagulation system, protein C is activated by thrombin and it then 
inactivates FVa in a negative feedback loop (Esmon 2001). Human FVa is 
inactivated by activated protein C (APC) proteolytic cleavages at three cleavage 
sites on heavy chain: Arg306, Arg506 and Arg679 (Kalafatis et al. 1994; Mann et al. 
1997). These three cleavage sites are not conserved in PCNS (Rao et al. 2003b). 
Arg316 is proposed to be an alternative cleavage site at which APC can still 
inactivate mammalian FV but at a lower rate (van der Neut et al. 2004). However, 
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even this alternative Arg316 cleavage site is absent in PCNS (Rao et al. 2003b). 
Thus, firstly all cleavage sites have been modified in PCNS to confer it resistance 
to APC inactivation. Secondly, as phosphorylation is speculated to be important 
for regulating the inactivation of FVa by APC (Kalafatis 1998). The lack of the 
phosphorylation site (Ser692) makes PCNS a less preferred APC substrate (Rao et 
al. 2003b). Thirdly, the constant association with PCCS affords PCNS the 
resistance to APC inactivation (Rao et al. 2003b). Overall, PCNS is a functional 
and structural homologue of mammalian FVa and group C prothrombin activator 
complex is similar to “FXa-FVa” complex. 
 
Presence of Parallel Prothrombin Activator Systems in  
Australian Elapid Snakes 
As snakes are vertebrates, their haemostatic system should contain blood 
coagulation factors. Thus the Australian elapid snakes possess parallel 
prothrombin activating systems: one in their venom which is used as an offensive 
weapon to attack the haemostatic system of the prey, and the other in their blood 
which they use for their own haemostatic purpose. Hence, it is interesting to 
examine the structural similarities between venom prothrombin activators and 
their respective plasma blood coagulation factors.  
 
Blood coagulation Factor X, Trocarin D and PCCS 
Coagulation factors are produced in liver and secreted into blood. 
Therefore, the cDNA sequence of the blood coagulation FX (TrFX) from the liver 
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of T. carinatus was determined (Reza et al. 2005a). The deduced TrFX sequence 
showed ~80% identity with trocarin D and ~50% identity with mammalian FX 
(Reza et al. 2005a). A comparison of TrFX against other FX sequences and 
trocarin D showed that it has similar domain architecture and conserved cysteine 
residues. However, the posttranslational modifications of TrFX, such as γ-
carboxylation, N- and O-glycosylation, are closer to trocarin D than mammalian 
FX (Reza et al. 2005a). The expression level of TrFX in the liver and trocarin D 
in the venom gland were investigated by quantitative real-time polymerase chain 
reaction (RT-PCR) and it was found that trocarin D is expressed ~30 times higher 
in the venom gland than TrFX in the liver (Reza et al. 2007). 
 
Similarly, the cDNA sequence of the blood coagulation factor X (PFX) 
was determined from the liver of P. textilis. Interestingly, two molecular isoforms 
of PFX (PFX1 and PFX2) were found (Reza et al. 2006). PFX1 and PFX2 share 
high percentage of identity in cDNA sequence (~85%) as well as at protein level 
(~81%) (Reza et al. 2006). The deduced amino acid sequences also show ~40-
50% identity with mammalian FX (Reza et al. 2006). Furthermore, both of these 
isoforms have molecular signatures and domain architecture of FX and group D 
prothrombin activators (Reza et al. 2006). The expression of PFX1, PFX2 in the 
liver and PCCS in the venom gland were also investigated using quantitative RT-
PCR. It was found that PFX1 is expressed ~55,000 times higher than that of PFX2 
in the liver and PCCS is expressed ~80 times higher in the venom gland than 
PFX1 in the liver (Reza et al. 2006). The results also confirmed their tissue-
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specific expression by detecting PFX1 and PFX2 only in the liver tissue and 
PCCS only in the venom gland tissue (Reza et al. 2006). 
 
The presence of trocarin D and TrFX in T. carinatus, and pseutarin C and 
PFX in P. textilis confirms the presence of parallel prothrombin activator systems 
in Australian elapid snakes and that the proteins are products of different genes. 
These results also provide the first direct evidence that venom prothrombin 
activators originate from gene duplication of blood coagulation factor genes. 
 
Evolutionary relationships of venom prothrombin activators and blood 
coagulation factors  
A detailed sequence analysis of the venom prothrombin activators 
(trocarin D and pseutarin C) and the plasma prothrombin activators (PFX1, PFX2 
and TrFX) reveals evolutionary relationships between them (Reza et al. 2005a; 
Reza et al. 2006). PFX1 has a higher identity (~94%) to TrFX than PFX2, 
whereas PFX2 shows higher identity (~90%) to PCCS and trocarin D than PFX1. 
A comparison of the activation peptides from the deduced amino acid sequences 
shows that, while the size of PFX1 activation peptide (57 residues) is identical to 
that of TrFX, the size of the shorter PFX2 activation peptide (27 residues) is 
identical to its venom counterparts, PCCS and trocarin D (Reza et al. 2006). PFX2 
also has an insertion in its heavy chain which is the exact position as that in PCCS 
and trocarin D. However, the insertion in PFX2 is nine residues long while the 
insertions in PCCS and trocarin D are 13 and 12 residues long respectively. These 
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patterns observed suggest that PFX2 is an intermediate between PFX1 and PCCS 
(Reza et al. 2006). Therefore, PFX2 is proposed to be an evolutionary 
intermediate and a “molecular fossil” of the evolution of venom prothrombin 
activators from blood coagulation factors (Reza et al. 2006).  
 
A phylogenetic tree of the snake venom and plasma prothrombin 
activators with other known FX sequences reveals more evolutionary 
relationships (Reza et al. 2006; St Pierre et al. 2005). All the reptilian sequences 
come out in a monophyletic group (Fig. 1.3) (Reza et al. 2006). Within the 
reptilian clade, group C and D prothrombin activators appear as two separate 
clades on the tree. Interestingly, the PFX2 sequence is found nested within the 
group C prothrombin activators. This enhances the theory that PFX2 is an 
evolutionary intermediate of PCCS from PFX1. Based on the topology of the 
phylogenetic tree, it is suggested that to the existence of snake venom 
prothrombin activators could have been established through three independent 
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Figure 1.3: Phylogenetic tree of snake venom prothrombin activators and 
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Blood coagulation Factor V and PCNS 
As with blood coagulation factors, FV is also produced in the liver and 
secreted into the blood. Hence, the cDNA sequence of blood coagulation FV 
(PFV) from the liver of P. textilis was determined (Minh et al. 2005). The 
deduced PFV amino acid has high similarities to PCNS (~96% identity), and 
human, chicken, and zebrafish FV (54%, 52%, and 44% identity respectively). It 
also has the same domain architecture as PCNS and FV from other organisms 
(Minh et al. 2005).  
 
Detailed comparisons revealed that, while the functionally important 
domain A and C of PFV and PCNS are highly conserved, the domain B of PFV 
and PCNS is the most variable segment of the proteins (Minh et al. 2005). The 
PFV domain B (126 residues) is also one residue shorter than that of PCNS (127 
residues), and this is much shorter than that of mammalian and non-mammalian 
FV. All of the FXa and thrombin proteolytic cleavage sites are conserved in PFV 
and PCNS but PFV has an additional FXa proteolytic cleavage site at Arg1765 
(Minh et al. 2005; Rao et al. 2003b). While PCNS is resistant to inactivation by 
APC (discussed above), PFV can be inactivated by APC as it has both Arg316 and 
Lys506 cleavage sites (Minh et al. 2005). From these comparisons, it can be seen 
that many of the potential post-translational modification sites are different (Minh 
et al. 2005). It can be postulated that PCNS might have evolved venom toxin 
properties, such as resistance to APC inactivation, by mutating these important 
residues. 
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Using gene-specific primers, a polymerase chain reaction (PCR) was 
carried out using the genomic DNA of P. textilis (Minh et al. 2005). As expected, 
PCR reactions using PFV-specific primers would only produce PFV-PCR 
products from liver tissues and PCNS-specific primers would only produce 
PCNS-PCR products from venom gland tissues (Minh et al. 2005). Subsequently, 
using RT-PCR we have shown that PCNS is expressed ~20 times higher in the 
venom gland than PFV in the liver (Minh et al. 2005). 
 
Difference in Expression and Regulation of  
Both Prothrombin Activator Systems 
Despite the overall similarities in structure and catalytic properties, 
distinct expression pattern of each prothrombin activator system enables them to 
carry out their distinct physiological roles (Table 2) (Reza et al. 2005b; Reza et al. 
2007). These differences are: (1) Tissue-specific expression. The plasma 
prothrombin activators are exclusively expressed in the liver and secreted in the 
plasma as zymogen; whereas the venom prothrombin activators are expressed 
only in the venom gland and prevails in its active form to instantly act on the 
coagulation system of the prey. (2) Expression levels. The venom prothrombin 
activators are expressed in the venom gland in high quantities compared to the 
expression of respective plasma prothrombin activators in liver (Joseph et al. 1999; 
Minh et al. 2005; Rao and Kini 2002; Reza et al. 2006; Reza et al. 2007). (3) 
Regulation of expression. In the liver, FX is expressed constitutively (Bahnak et 
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al. 1987; Miao et al. 1992) and hence it is produced at a steady state level. In 
contrast, the expression of venom prothrombin activators is inducible (Paine et al. 
1992; Rotenberg et al. 1971). Its expression reaches the maximum when the 
venom gland is empty, and its expression slows down or stops when the gland is 
full. To understand these differences in tissue-specific expression and regulation, 
the gene organization of these parallel systems was investigated. 
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Table 1.2: Comparison of the venom and plasma prothrombin activators. 
Venom Prothrombin Activators Plasma Prothrombin Activators 
Produced in the venom gland tissue Produced in the liver tissue 
Inducible expression Constitutive expression 
Higher levels of expression Lower levels of expression 
Secreted in the venom gland Secreted in the plasma 
Exist in active form Circulate in the plasma as zymogens 
Function as a toxin to immobilize 
the prey as well as for defense 
Function as haemostatic factors to 
survive vascular injuries 
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Figure 1.4: A. Cis-elements of human, murine, TrFX, trocarin D and PCCS promoter 
regions. The identification of cis elements in human and murine FX are experimentally supported, 
whereas cis elements in TrFX, trocarin D and PCCS promoter regions are predicted by sequence 
comparison (Huang et al. 1992; Reza et al. 2007; Wilberding and Castellino 2000) B. 
Comparison of TrFX and trocarin D intron one regions. 
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Gene Organization of Trocarin D and Tropidechis carinatus FX (TrFX) 
Similar to mammalian FX genes, trocarin D and TrFX genes have eight 
exons interspersed with seven introns with identical exon-intron boundaries. Their 
gene organization revealed that the gene structures are similar with differences 
only in the promoter and intron 1 region (Fig. 1.4) (Reza et al. 2007).  
 
Promoter Region 
Trocarin D promoter is nearly identical to TrFX promoter except for a 264 
bp insert spanning from -33 to -297 bp upstream of the start codon (Fig. 1.4A). In 
order to characterize the promoter region, the trocarin D and TrFX promoter 
regions were  compared against those of human (Hung et al. 2001; Hung and 
High 1996) and murine (Wilberding and Castellino 2000) FX which has been 
previously characterized. Human FX has four conserved cis-regulatory elements 
(Fig. 1.4): (i) a CCAAT box (Hung et al. 2001; Hung and High 1996; Wilberding 
and Castellino 2000), (ii) a gut-specific transcription factor GATA-4 binding site  
(Hung et al. 2001), (iii) a liver-specific transcription factor HNF-4 (Hung and 
High 1996), and (iv) multiple Sp1/Sp3 binding sites (Hung et al. 2001). The 
overlapping trocarin D and TrFX promoter regions have similar transcription 
factor binding sites compared to mammalian and murine FX, and hence should 
interact with similar trans-regulatory elements (Reza et al. 2007). As the 264 bp 
insertion in the trocarin D promoter region was novel, bioinformatics tools were 
used to characterize it. The analysis reveals that there are three TATA-like boxes 
(TLB), a Y-box and a GATA-4 binding site within the insertion (Fig. 1.4) (Reza 
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et al. 2007). Interestingly, there is a similar insertion with identical predicted 
regulatory cis-elements in the promoter region of PCCS (Fig. 1.4) (Reza et al. 
2007). Therefore, it seems that this segment could play an important role in the 
switching the steady constitutive expression of FX to the high inducible 
expression of the venom prothrombin activators.  Hence, this segment was named 
as Venom Recruitment/Switch Element (VERSE). 
 
Intron 1 Region 
Both trocarin D and TrFX introns are similar (92-99% identity) with only 
differences in intron 1. The size of the trocarin D intron 1 is 7911 bp compared to 
5293 bp in TrFX, and this difference in size is accounted by three insertions and 
two deletions in trocarin D  (Fig. 1.4B) (Reza et al. 2007). The three insertions are 
214 bp, 1975 bp and 2174 bp in size whose respective positions are at 128 bp, 914 
bp and 3300 bp on the trocarin D gene. These three inserts are unique and show 
no significant similarity to any known DNA sequences (Reza et al. 2007). 
However, there are some patterns amongst these three inserts. The first insert is 
almost an exact repeat (96.33% identity) with the trocarin D intron segment 
spanning from 3082 bp to 3299 bp. The other two inserts seem to be inverted 
repeats of each other (~71% identity). The third insert shows all the major 
characteristics of a S/MAR region: (i) a long stretch of a high AT rich content 
(Cockerill and Garrard 1986; Liebich et al. 2002; Zhou and Liu 2001), (ii) a 
topoisomerase II (Boulikas 1993), (iii) a S/MAR consensus motif (van Drunen et 
al. 1997), (iv) a significant over-representation of characteristic hexanucleotides 
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(Liebich et al. 2002), and (v) ATTA motif and an AT-rich region with H-box 
(Will et al. 1998). The two deletions are 255 bp and 1406 bp in size whose 
respective positions are at 2610 bp and 3770 bp on the TrFX gene (Reza et al. 
2007). Interestingly, PCCS intron 1 also has three insertions and two deletions 
when it is compared against the intron 1 region of PFX1. The size and location of 
the PCCS insertion segments are similar to those of trocarin D but there are 
differences in the size and location of the PCCS and trocarin D deletion segments. 
However, there are regions of similarity when the nucleotide sequences of the 
trocarin D and PCCS insertion/deletion segments are compared (Pang Shu Yi, 
2007). 
 
These insertions and deletions in the promoter and intron 1 regions are 
probably responsible for the change in expression levels and tissue-specificity 
between trocarin D and TrFX (Reza et al. 2005b; Reza et al. 2007).  
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 AIMS AND SCOPE 
Our laboratory has characterized extensively characterized trocarin D, a 
group D snake venom prothrombin activator, from the venom of Tropidechis 
carinatus. We have shown it to be functionally and structurally similar to 
activated mammalian blood coagulation factor X (FXa). A snake FX-like cDNA 
sequence (TrFX) was determined from the liver of Tropidechis carinatus. Despite 
high sequence similarities, there are significant differences to indicate that 
trocarin D and TrFX are encoded by two different genes. Real-time PCR reveal 
differences in expression patterns. Trocarin D has an elevated level and venom 
gland-specific expression, and TrFX has a low level and liver-specific expression 
pattern. The gene organizations were determined to understand the underlying 
causes of these differences in expression patterns.  
 
Comparison of the trocarin D and TrFX gene sequences show differences 
within their promoter and the intron 1 regions. Trocarin D has a 264 bp insertion 
in its promoter region. Besides the VERSE promoter insertion, the trocarin D 
intron 1 region has three insertions and two deletions compared to that of TrFX. 
In the insertion 2 segment, there is a potential scaffold matrix attachment region 
which has been known to have gene up-regulatory influence. All these VERSE 
promoter and intron insertion/deletion segments are novel and could contain 
regulatory cis-elements which affect transcription, and hence, expression. These 
genetic differences are hypothesized to be responsible for the differences in 
expression patterns.  
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This thesis aims to characterize the trocarin D VERSE promoter and intron 
1 insertion/deletion regions for their roles in regulating elevated and tissue-
specific expression. Specifically, the aims of this thesis are: 
 
1. To characterize the VERSE promoter for its role in “venom recruitment” 
using site-directed mutagenesis and 5’/3’ deletion luciferase assays in 
primary snake venom gland cells and mammalian cell lines. 
2. To characterize the trocarin D intron 1 insertion and deletion segments for 
their roles in tissue-specific expression using 5’/3’ deletion luciferase 
assays in mammalian cell lines. 
3. To identify and characterize the trans-factor elements which interact with 
the identified VERSE cis-elements using a series of proteomics techniques. 
 
On the whole, the scope of the thesis covers the approaches used to fulfill 
these aims, the results obtained, and the discussion of their implications. 
Explicitly, we have characterized the trocarin D VERSE promoter and intron 1 
insertion/deletion segments using a series of site-directed mutagenesis and serial 
deletion luciferase assays. The VERSE cis-elements which were previously 
predicted using bioinformatics tools were characterized and confirmed. In 
addition, three additional novel cis-elements (Sup, Up1 and Up2) were identified. 
These novel cis-elements were characterized for their roles in regulating trocarin 
D expression. Electrophoretic mobility shift assays were performed to determine 
that these novel cis-elements interact with nuclear proteins. The trans-factor 
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which interacts with the Sup cis-element was purified using DNA-affinity 
chromatography and identified as a POU domain, class 6 transcription factor 
using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass 
Spectrometer. Lastly, the trocarin D intron 1 insertion/deletion segments were 
also characterized using deletion luciferase assays. A 26 bp silencer cis-element 
was identified within trocarin D intron 1 insertion 2 segment. Using 
bioinformatics tools, this silencer motif is also found in the intron 1 regions of 
PCCS and several other snake venom toxins. This highlights the intron 1 region of 
snake venom toxins as a potential regulator for tissue-specific expression. This 
thesis has contributed and extended the limits of snake venom toxin research. 












Characterization of trocarin D  
VERSE promoter 
 
Chapter II – Characterization of trocarin D VERSE promoter 
51 
INTRODUCTION 
Research in genomics initially started out by compiling the genes that 
make up an organism’s genome. With the help of faster and cheaper DNA 
sequencing technology, more genomes are being completed and annotated. In 
recent times, the question has now been shifted to explore the “switches” that 
determine which gene gets activated in a specific tissue at a particular time. Gene 
regulation is a complex event with ranges from transcription and all the way to 
post-translation modifications. There are many switches along the way which 
keeps this a tightly regulated phenomenon. The focus of this chapter is at the 
transcription level. At this stage, regulatory cis-elements are short DNA 
sequences in the non-coding regions of a gene that control transcription (Wray 
2007). These cis-elements can be found within the promoter region and those that 
are far from the promoter regions are known as enhancers (James D.Watson et al. 
2007). These regulatory cis-elements interact with the transcription factors present 
in the nucleus and recruit them to the promoter region. Depending on the type of 
transcription factors recruited, transcription is either initiated or prevented. Once 
transcription occurs, the transcribed mRNA will be exported from the cell nucleus 
to the cytoplasm for translation into a functional protein.  
 
As discussed in chapter 1, the gene organizations of trocarin D and 
Tropidechis FX (TrFX) are compared and a 264 bp insertion is revealed in the 
trocarin D promoter region (Fig. 1.4). TrFX is expressed specifically in the liver 
at low constitutive levels (Reza et al. 2007). Therefore, this insertion is postulated 
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to have a transcription regulatory role which is incorporated during accelerated 
evolution after gene duplication to allow the twin gene to be expressed 
specifically in the venom glands at high amounts. This trocarin D promoter 
insertion is termed as Venom Recruitment/Switch Element (VERSE) (Reza et al. 
2007).  
 
While it is possible that differences between the available transcription 
factors that exist between the two cell types could also account for the differences 
in expression patterns, this chapter focuses on exploring how differences in cis-
elements could affect gene regulation. In this case, the question of how the 
insertion of VERSE alters the gene regulation from a low and liver specific 
expression to one that is high and venom gland specific will be addressed in this 
chapter. This VERSE segment is novel and contains several putative cis-elements: 
one GATA-4 box, one Y box and three TATA-like boxes (TLB1- TLB3) (Fig. 
1.4). The VERSE promoter is characterized for its cis-elements using luciferase 
assays in primary snake venom gland cells and mammalian cell lines. 
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MATERIAL & METHODS 
Materials 
T. carinatus fresh venom glands and liver tissues were provided by 
Venom Supplies Pty Ltd, Tanunda, South Australia. The DNeasy Tissue kit and 
RNeasy Mini kit were purchased from Qiagen (Valencia, CA, USA). The Long 
PCR Enzyme Mix was purchased from Fermentas (Hanover, MD, USA). The cell 
culture media were purchased from Sigma (St. Louis, MO, USA). The FuGENE 6 
transfection reagent was purchased from Roche Diagnostics (GmbH, Deutschland, 
Germany). The pGEM®-T Easy vector, luciferase vectors (pGL4.10, pGL4.13, 
pGL4.70, pGL4.73 and pGL4.75) and Dual-GloTM Luciferase Assay System were 
purchased from Promega Corporation (Madison, WI, USA). The GeneAll Plasmid 
Quick kit was purchased from GeneAll Biotechnology (Seoul, Korea). 
Oligonucleotides primers were ordered from 1st BASE (Singapore). The SMART 
RACE cDNA Amplification kit and Advantage 2 PCR Enzyme system were 
purchased from Clontech Laboratories Inc. (Palo Alto, CA, USA). The ABI 
PRISM® BigDye® terminator cycle sequencing ready reaction kit was purchased 
from Perkin Elmer (Foster City, CA, USA).  
 
T. carinatus Liver Tissues and Genomic DNA Extraction 
Genomic DNA (gDNA) was extracted from T. carinatus liver tissues 
using the DNeasy Tissue kit according to the manufacturer’s instructions. For 
each extraction, 30 mg of liver tissue was taken and RNaseH was used to prevent 
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RNA contamination. The gDNA integrity was examined using 0.8% agarose gel 
electrophoresis and checking its optical density. 
 
Luciferase Constructs for the Characterization of VERSE 
Based on the gene sequence of TrFX and trocarin D, primers were 
designed to amplify the TrFX, trocarin D and VERSE promoter segments from the 
T. carinatus gDNA using standard PCR protocols with Long PCR Enzyme Mix. 
To investigate the gene regulatory influence of the VERSE cis-elements, 
deletion/site-directed mutagenesis were made to VERSE. Individual site-directed 
mutagenesis was done to the predicted cis-elements (TLB2, TLB3, GATA box 
and Y box) and novel cis-elements (Up1, Up2 and Sup) using a series of fusion 
PCR protocols. These mutants are named mTLB2, mTLB3, mGATA, mYbox, 
mUp1, mUp2 and mSup, respectively (Fig. 2.2 and 2.5). TLB1 was considered to 
be a nonfunctional cis-element as it is downstream of the transcription start site. 
Eight 5’ serial deletion constructs (5.1 - 5.8) were made by deleting ~15 bp each 
time. One 3’ deleted construct (VTss) was made by deleting 61 bp from the 3’ end 
of VERSE. Based on the deletion assays, a VERSE minimal core promoter (MCP) 
segment was identified and amplified. TrFX, trocarin D, VERSE and modified 
VERSE promoter PCR products were directionally cloned into the promoter-less 
pGL4.10 vector containing the firefly luciferase reporter gene. The primers used 
for constructing the VERSE constructs are listed in the Appendix. 
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All constructs were verified by DNA sequencing using ABI PRISM® 
BigDye® terminator cycle sequencing ready reaction kit according to the 
manufacturer’s instructions. 
 
Luciferase Constructs for Comparison against CMV Promoter  
The up-regulatory potency of VERSE was investigated by comparing it 
against the CMV promoter. For this comparison, VERSE was directionally cloned 
into the promoter-less pGL4.70 vector containing the Renilla luciferase reporter 
gene. The luciferase activity of this VERSE-pGL4.70 construct was compared 
against the pGL4.75 vector which contains the Renilla luciferase gene whose 
expression is driven by the CMV promoter. 
 
Culture of Primary P. textilis Venom Gland Cells and Mammalian Cell Lines  
To characterize VERSE in its native tissue environment, luciferase 
constructs were transfected into primary venom gland cells. Five fresh pairs of P. 
textilis venom glands were minced and passed through a fine sieve to break up the 
tissue. The cell suspension was trypsinized to obtain a mono-cell culture. The 
primary venom gland cell culture was maintained in CMRL media with 10% fetal 
bovine serum and 1% penicillin-streptomycin. Primary P. textilis venom gland 
cells were incubated at 30 °C in a humidified atmosphere containing 5% CO2.  
 
For further characterization of VERSE, luciferase constructs were 
transfected into three mammalian cell lines, CHOK1, HepG2 and HEK293T cells. 
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CHOK1 and HepG2 cell lines were maintained in DMEM media supplemented 
with 10% fetal bovine serum and 0.1% gentamycin. HEK293T cell line was 
maintained in RPMI media supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin. All mammalian cell lines were incubated at 37 °C in a 
humidified atmosphere containing 5% CO2.  
 
Transfection and Luciferase Assays 
Cells were seeded into 96-well plates at a density of 5 x 103 cells per well. 
The mammalian cells were grown to ~70% confluency before transfection. For 
the characterization of VERSE, the transfection efficacy was normalized by co-
transfecting 750 ng of insert-pGL4.10 firefly luciferase reporter construct with 1 
ng of pGL4.73 vector containing the Renilla luciferase gene controlled by the 
SV40 promoter. For the comparison of VERSE against the CMV promoter, the 
transfection efficacy was normalized by co-transfecting 750 ng of the VERSE-
pGL4.70/CMV-pGL4.75 Renilla reporter construct with 1 ng of pGL4.13 vector 
containing the firefly luciferase gene controlled by the SV40 promoter.  
 
Cells were transfected using FuGENE 6 transfection reagent according to 
the manufacturer’s instruction. After 24 h, luciferase activity was measured using 
the Dual-GloTM Luciferase Assay System according to the manufacturer’s 
instructions in a GloMax™ Luminometer from Promega Corporation (Madison, 
WI, USA). Relative light units were calculated by dividing the luciferase signals 
by their corresponding normalizing luciferase signals.  
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Data Analysis 
All luciferase activities were tabulated relative to that of VERSE which 
was taken as 100%. All luciferase assays were performed in triplicate. While 
luciferase assays were carried out in primary P. textilis venom gland cells only 
once, luciferase assays were repeated at least three independent times in 
mammalian cell lines. The luciferase activity of each construct represents the 
mean of all its assays.  
 
RNA Isolation and 5’ RACE 
To determine the influence of TLB2 and TLB3 on the transcription start 
site, 5’ RACE libraries was performed for the VERSE, mTLB2 and mTLB3 
constructs. The constructs were transfected into HEK293T cells using FuGENE 6 
transfection reagent as described previously. After 24 h, luciferase activity was 
measured to confirm the success of transfection. Total RNA was isolated from the 
transfected HEK293T cells using the RNeasy Mini kit following the 
manufacturer’s instruction. The quality of RNA was checked by 1% agarose gel 
electrophoresis and was quantified by checking the optical density. A 5’ RACE 
library was created and amplifications for each construct using the SMART 
RACE cDNA Amplification kit and Advantage 2 PCR Enzyme system. The 
initial amplification was carried out with the Universal primer mix (UPM) 
provided by the kit and gene-specific oligonuceotide (GSP1). The primary PCR 
products were reamplified using the nested UPM provided and a second gene-
specific primer (GSP2) which was designed upstream of the GSP1. The gene 
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specific primers, GSP1 and GSP2, were designed based on the pGL4.10 vector 
sequence (shown in the Appendix). 
 
Cloning and Sequencing of 5’ RACE Products  
The 5’ RACE products were ligated to pGEM®-T Easy vector according 
to the manufacturer’s instructions. Ligated products were transformed into DH5α 
Escherichia coli chemically competent cells using heat shock. Ampicillin (100 
mg/ml) was used for selection against antibiotics. Blue/white colony screening 
was performed on LB agar plates using X-gal (80 mg/ml) and isoprophyl-b-D-
thiogalacto-pyranoside (100 mM). White clones were selected and inoculated in 2 
ml of LB broth 37 °C overnight at 200 rpm. Plasmids were extracted using the 
GeneAll Plasmid Quick kit and checked by EcoR1 digestion to determine the 
presence of inserts. All sequencing reactions were carried out using ABI PRISM® 
BigDye® terminator cycle sequencing ready reaction kit according to the 
manufacturer’s instructions. 
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RESULTS 
The Role of VERSE in the Expression of Trocarin D 
To compare their gene regulatory effects, luciferase gene under the control 
of TrFX and trocarin D and VERSE promoters were transfected into HepG2, 
HEK293T and CHOK1 cell lines. The promoter activity of 618 bp trocarin D 
promoter was 19, 29, 49 folds higher than that of 341 bp TrFX promoter in 
HepG2, HEK293T and CHOK1 cell lines, respectively (Fig. 2.1). The promoter 
activity of VERSE was comparable to that of the trocarin D promoter in all three 
cell lines (Fig. 2.1). This indicates that VERSE is the main promoter segment 
responsible for the elevated expression level of trocarin D. Site-directed 
mutagenesis was carried out to knock out the individual predicted VERSE cis-
elements to determine their influences on gene regulation. 
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Figure 2.1: Comparison of TrFX, trocarin D and VERSE promoter activities 
in mammalian cell lines. Firefly luciferase genes under the control of TrFX, 
trocarin D and VERSE promoters were transfected into HepG2, HEK293T and 
CHOK1 cell lines. Renilla luciferase genes under the control of the SV40 
promoter were co-transfected as internal controls. Firefly luciferase activities of 
the various constructs were normalized against the Renilla luciferase activities 
and are shown relative to that of the VERSE promoter. The results are the mean 
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The Role of Predicted VERSE Cis-elements in Regulating Expression  
VERSE contains one each of GATA-4 and Y boxes, and three TATA like 
boxes (TLB1 - TLB3). These cis-elements have a positive effect on transcription 
in other genes (Blissard et al. 1992; Hung et al. 2001; Tafuri and Wolffe 1990). 
As TLB1 is downstream of the transcription start site, it was considered as 
nonfunctional and was not characterized further. Site-directed mutations to other 
putative cis-element sites in VERSE were done to determine their role in gene 
regulation. The luciferase activity of the mGATA, mYbox and mTLB2 constructs 
were 11-51%, 42-70% and 36-62% lower compared to the VERSE promoter, 
respectively (Fig. 2.2). A significant decrease in luciferase activity due to their 
mutations confirms the role of the GATA-4 box, Y box and TLB2. Contrary to 
expectations, the knocking out of TLB3 (construct mTLB3) results in a 14-25% 
increase in luciferase activity (Fig. 2.2).   
 
Mammalian Cell Lines as Reasonable Substitutes for Snake Venom Gland 
Cells 
As no immortal snake venom gland cell lines are available, VERSE was 
initially characterized using primary venom gland cells from P. textilis. To 
minimize the number of sacrificed snakes and to obtain sufficient cells for the 
luciferase assays, the larger P. textilis venom glands were chosen over T. 
carinatus. Despite the difference in species, the characterization of VERSE would 
not be affected as similar VERSE segments (~95% identity) are inserted in the 
promoter regions of trocarin D and PCCS (Reza et al. 2007). The results of the 
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luciferase expression studies conducted using the P. textilis venom glands were 
parallel to those from the mammalian cell lines (Fig. 2.2). This indicates that 
HepG2, HEK293T and CHOK1 mammalian cell lines are reasonable substitutes 
for venom gland cells to characterize VERSE. Hence, VERSE was further 
characterized using these mammalian cell lines. 
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Figure 2.2: Characterization of predicted VERSE cis-elements and 
comparison of VERSE promoter activity between primary P. textilis venom 
gland cells and mammalian cell lines. Site-directed mutagenesis was performed 
to each predicted VERSE cis-element. Firefly luciferase genes under the control of 
the modified VERSE promoters were transfected into primary P. textilis venom 
gland cells and HepG2, HEK293T and CHOK1 cell lines. Renilla luciferase genes 
under the control of the SV40 promoter were co-transfected as internal controls. 
Firefly luciferase activities of the various constructs were normalized against the 
Renilla luciferase activities and are shown relative to that of the VERSE promoter. 
The luciferase activities from the primary venom gland cells are the mean of one 
experiment carried out in triplicates whereas the luciferase activities from the 
mammalian cell lines are the mean of at least three independent experiments, each 
carried out in triplicates. 
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Role of TLB2 and TLB3 on Transcription Initiation 
TATA boxes direct the RNA polymerase II to initiate transcription 
approximately 30 bp downstream of their location (Buratowski et al. 1989; 
Concino et al. 1984; Thomm 1996). To examine the influence that TLB2 and 
TLB3 have on transcription initiation, a total of 19, 14 and 17 random 5’ RACE 
clones for the VERSE, mTLB2 and mTLB3 constructs were successfully 
sequenced, respectively. From the 5’ RACE products of mTLB3 and mTLB2, it 
can be observed that TLB2 and TLB3 were able to initiate transcription when 
either one was knocked out (Fig. 2.3). However, the transcription start sites of the 
VERSE construct coincided with those initiated by TLB2 (construct mTLB3) (Fig. 
2.3). This indicates that TLB2 is the sole functional TATA box in VERSE. 
Despite its similarity to the TATA box consensus sequence, TLB3 may detract 
from a more efficient transcription initiation by TLB2. The mechanism by which 
the role of TLB3 is suppressed in snake venom glands is not clear.   
 
It is noted that the transcription start sites of VERSE are identical to those 
of trocarin D (Fig. 1.4). This confirms that VERSE is responsible for transcription 
initiation of trocarin D. Its insertion in the trocarin D promoter has caused an up-
shift in the TrFX promoter cis-elements, and hence, taking over as the core 
promoter segment (Fig. 2.3). 


















TLB1TLB3GATA-4 Y box TLB2
Figure 2.3: Influence of TLB3 and TLB2 on transcription start sites. 
Transcription start sites of trocarin D (3), and 5’ RACE products of VERSE, 
mTLB3 and mTLB2 are shown. A total of 19, 17 and 14 clones are sequenced for 
VERSE, mTLB3 and mTLB2, respectively. The arrows indicate transcription start 
sites. The positions of transcription start sites are indicated next to the arrow and 
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 Identification of Novel Cis-elements and Minimal Core Promoter in VERSE  
To reveal cis-elements that were previously not identified, luciferase 
expression constructs containing 5’ serial and 3’ deletion of the VERSE were 
generated. All three mammalian cell lines showed similar trends in the expression 
of luciferase activity. Comparison of constructs 5.1 and 5.2 shows a 32-48% 
decrease in luciferase activity (Fig. 2.4), and this indicates the presence of an up-
regulatory cis-element (Up2) between -156 and -140 bp. Comparison of 
constructs 5.2 and 5.3 shows a 12-22% increase in luciferase activity (Fig. 2.4), 
and this indicates the presence of a suppressor element (Sup) between -140 and -
125 bp. Further deletion from the 5’ end of the VERSE segment revealed another 
up-regulatory cis-element (Up1) between -101 and -84 bp when the luciferase 
activity decreased 16-36% between constructs 5.4 and 5.5 (Fig. 2.4). The 
decreases in luciferase activity between constructs 5.5 to 5.8 are accounted for by 
the deletion of the TLB2, TLB3 and Y box cis-elements. There are no new cis-
elements that reside within -84 to -21 bp of the VERSE region. One suppressor 
(Sup) and two up-regulatory cis-elements (Up1 and Up2) have been identified and 
found to be novel.  
 
From the 3’ deletion assays, the luciferase activity of VTss was 
comparable to that of VERSE (Fig. 2.4). This shows that the +18 to +83 bp 
downstream segment of the transcription start site contains no gene regulatory cis-
elements and confirms that TLB1 is nonfunctional. Based on the deletion assays, 
it is observed that construct 5.3 and VTss have luciferase activities that are 
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comparable to VERSE. This identifies the -125 to +18 bp region to be the minimal 
core promoter region. The luciferase activity of MCP is comparable to that of the 
VERSE promoter (Fig. 2.4).  
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Figure 2.4: Characterization of VERSE promoter by serial deletions and 
identification of minimal core promoter. Serial deletions were made to the 5’/3’ 
ends of VERSE. Firefly luciferase genes under the control of the modified VERSE 
promoter were transfected into HepG2, HEK293T and CHOK1 cell lines. Serial 
deletion results were combined to identify the minimal core promoter. Renilla 
luciferase genes under the control of the SV40 promoter were co-transfected as 
internal controls. Firefly luciferase activities of the various constructs were 
normalized against the Renilla luciferase activities and are shown relative to that 
of the VERSE promoter. The results are the mean of at least three independent 
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The Role of Novel VERSE Cis-elements in Regulating Expression  
Site-directed mutagenesis of the above novel cis-elements was performed 
to understand their identities and gene regulatory roles. Individual mutations of 
Up1 and Up2 (mUp1 and mUp2 constructs, respectively) resulted in 38-88% and 
18-60% decreases in luciferase activities, respectively (Fig. 2.5). This confirms 
the importance of Up1 and Up2 cis-elements in the up-regulation of gene 
expression. 
 
Contrary to the 5’ serial deletion assays, the luciferase activity of the mSup 
construct is 36-46% lower than that of VERSE (Fig. 2.5). This suggests that Sup 
functions in tandem with other cis-elements for gene regulation, and its mutation 
could have affected the functions of its partnering cis-elements. Base on the 
similar luciferase activities of construct 5.3 and mSup, this suggests that the 
partnering cis-element partner is upstream of Sup. Hence, this partnering cis-
element is Up2. The role of Sup and its relationship with Up2 needs to be further 
investigated. 
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Figure 2.5: Characterization of novel cis-elements constructs. Site-directed 
mutagenesis was performed to each of the novel cis-elements constructs. Firefly 
luciferase genes under the control of the modified VERSE promoters were 
transfected into HepG2, HEK293T and CHOK1 cell lines. Renilla luciferase 
genes under the control of the SV40 promoter were co-transfected as internal 
controls. Firefly luciferase activities of the various constructs were normalized 
against the Renilla luciferase activities and are shown relative to that of the 
VERSE promoter. The results are the mean of at least three independent 
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 Comparison of VERSE and CMV Promoters 
CMV enhance/promoter is the most commonly used promoter to drive the 
expression of recombinant proteins in mammalian cell lines (Boshart et al. 1985; 
Foecking and Hofstetter 1986). The CMV enhancer/promoter in the pGL4.75 
luciferase vector is 741 bp in length. VERSE has an up-regulatory effect that is 
similar to the CMV promoter in the HEK293T cell line (Fig. 2.6). However, the 
luciferase activity of VERSE is 11 and 28 times lower than that of the CMV 
promoter in HepG2 and CHOK1 cell lines (Fig. 2.6). This indicates that VERSE 
can be further characterized to be a potential promoter for recombinant protein 
expression in HEK293T cell line.   
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Figure 2.6: Comparison of VERSE and CMV promoter activity. Renilla 
luciferase genes under the control of the modified VERSE promoters were 
transfected into HepG2, HEK293T and CHOK1 cell lines. Firefly luciferase genes 
under the control of the SV40 promoter were co-transfected as internal controls. 
Renilla luciferase activities of the various constructs were normalized against the 
Firefly luciferase activities and are shown relative to that of the CMV promoter. 
The results are the mean of at least three independent experiments, each carried 
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DISCUSSION 
In this chapter, the trocarin D VERSE promoter is characterized for its cis-
elements using luciferase assays in primary venom gland cells and mammalian 
cell lines. From the comparison of the VERSE, TrFX and trocarin D full promoter, 
it is evident that VERSE is responsible for the elevated level of the trocarin D 
gene expression. The trocarin D and VERSE promoter constructs have luciferase 
activities that are ~30 folds higher than that of the TrFX promoter construct. This 
increase in promoter activity of trocarin D coincides with the previous real time-
PCR report that trocarin D is expressed ~30 times higher in the venom gland than 
TrFX in the liver (Reza et al. 2007). An important point to note is that trocarin D 
has a venom gland specific expression and its expression was not detected in liver 
tissues (Reza et al. 2007). Trocarin D should not be expressed at all in liver 
tissues. However, inclusive of CHOK1 and HEK293T cell lines, VERSE is able to 
drive the expression of luciferase particularly in HepG2 cell lines at a level which 
is significantly higher than the TrFX promoter. HepG2 is a human liver cell line. 
Therefore, it is evident that the venom gland specific cis-elements of the trocarin 
D gene do not reside within the VERSE promoter element. Therefore, one can 
expect that such an element would reside within the trocarin D intron 1 
insertions/deletions or it might be an enhancer that further upstream of the 
characterized trocarin D promoter. 
 
VERSE is characterized for its cis-elements that are responsible for the 
elevated level of trocarin D gene expression. As VERSE is part of a gene which 
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belongs to the snake genome and functions in the venom gland, it should ideally 
be characterized in a snake venom gland cells. However, there are no available 
snake venom gland cell lines. Therefore, VERSE was initially characterized using 
primary P. textilis snake venom gland cells. As mammalian cells lines present a 
more ethical, less costly and readily available cell model for characterization 
VERSE was also characterized using mammalian cell lines. The luciferase 
expression results in mammalian cell lines were parallel with those in snake 
venom gland cells. Hence, mammalian cell lines are reasonable substitutes for 
snake venom gland cells for the further characterization of VERSE. This is the 
first time such a comparison has been done. Therefore, it paves the way for 
further characterization of other snake genes using mammalian cell lines.  
 
The site-directed mutagenesis assays confirm the presence and identity of 
the predicted cis-elements. VERSE contains one each of GATA-4 and Y boxes, 
and two TATA-like boxes (TLB2 - TLB3). TLB1 was not characterized as it was 
downstream of the transcription start site and was deemed nonfunctional. As there 
are two TATA-like boxes present, 5’ RACE assays were performed to determine 
which TATA box was the main cis-element that determines the transcription start 
site. It is shown that TLB2 and TLB3 are individually functional TATA box. 
However, when both are present, TLB2 is the primary TATA box which initiates 
transcription. The mechanism which silences transcription initiation at TLB3 in 
VERSE has not been elucidated. However, it postulated the other cis-elements 
could also play a role in preferring TLB2 as the main TATA box. Besides the 
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predicted cis-elements, three novel cis-elements are further identified from the 
deletion assays. The site-directed mutagenesis studies indicate that Up1 and Up2 
have up-regulatory effects, and that Sup could work in tandem with Up2 to up-
regulate the expression of trocarin D. This interaction between Sup and Up2 
needs to be further characterized. The identification and characterization of the 
trans-factors that interact with these novel cis-elements will give us more 
information about their role and importance in transcription regulatory network of 
trocarin D. However, in order to get a real idea regarding the functions of these 
novel cis-elements, site-directed mutagenesis studies have to be confirmed using a 
primary or snake venom gland cell line. In summary, VERSE has been 
characterized for its cis-elements. It contains one each of GATA-4 and Y boxes, 
two TATA like boxes (TLB2 - TLB3), and three novel cis-elements (Sup, Up1 
and Up2) (Fig. 2.7). Also, the nucleotides between -125 to +18 bp of VERSE have 
been identified as the minimal core promoter region.  
 
In order to find out the potency of the VERSE promoter, it was compared 
against the promoter activity of the CMV viral promoter. VERSE shows 
comparable up-regulatory effects on luciferase expression as CMV viral 
enhancer/promoter in HEK293T cell lines. This indicates the potential of VERSE 
to be further developed into a promoter for driving recombinant protein 
expression in mammalian cell lines, especially HEK293T cells. Two mutant 
constructs (MCP and mTLB3) showed modifications which could increase and 
improve the potential of VERSE as an expression promoter. The MCP construct is 
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able to retain the VERSE activity while being smaller in size (Fig. 2.4). It is 
approximately half the size of VERSE (143 bp) and about one-fifth the size of the 
commonly used CMV enhancer/promoter (741 bp). This reduction in size gives an 
advantage to the expression vector as it could possible allow a bigger cDNA to be 
inserted for expression. By mutating TLB3, the mTLB3 construct has a ~20% 
increase in luciferase activity compared to VERSE (Fig. 2.2). The combinations of 
these two mutations would possibly result in a more potent and smaller promoter 
compared to the CMV viral enhancer/promoter. 
 
This chapter first set out to answer the initial question of how the VERSE 
insertion is able to alter gene regulation from a low and liver specific expression 
to one that is high and venom gland specific. The results reveal that the cis-
elements within VERSE are responsible for elevating the expression of trocarin D 
but not control its tissue-specific expression. The following chapters will attempt 
to answer the second half of the question by investigating the gene regulatory 
roles of the trocarin D intron 1 insertions/deletions for regulatory role on tissue-
specific expression. 
Chapter II – Characterization of trocarin D VERSE promoter 
77 













Trocarin D VERSE 
             Up2        Sup 
TGTAGTGTACTTGTTTGCATACTCGTAATACTGCATTCCTATTGGACAGAT
       GATA-4 box    Up1 
ACCATCGCTTAACGATTGGTAGATAACAACAGTTCTAATTGGCCGCCTAAG
                TLB3                 Y box                   
CGATGGGAGTTTTAAATAAATGCCATTGGTTGCGAGCCGCGAGCAGCCGCT
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INTRODUCTION 
As previously mentioned many snake venom toxins are recruited from 
body proteins by gene duplication and accelerated evolution. The duplicated twin 
gene undergoes mutations/modifications to function better as a toxin, and 
importantly, to be exclusively expressed within the venom gland. Unregulated 
expressions of these toxins in any other tissue would be fatal to the organism. 
With regards to characterizing silencer cis-element, a lot of research in the past 
decade has been to characterize silencer cis-elements which control the neuron 
specific expression of neuronal genes (Mieda 1997; Shimojo and Hersh 2004). 
However, not much focus has been given towards identifying silencer cis-
elements in venom toxin genes. Therefore, this chapter aims to address what 
controls venom gland specific expression of these toxin genes by identifying their 
silencer cis-element. 
 
Base on the literature, the closest work that has been done regarding 
silencer cis-elements and venom toxin genes is to characterize a silencer element 
within the promoter region of α-neurotoxin gene in Naja sputatrix (Ma et al. 
2002). Ma et al. 2001 first characterized the N. sputatrix cardiotoxin and α-
neurotoxin gene, and found that both evolved by gene duplication and accelerated 
evolution. However, the cardiotoxin protein constitutes 60% of the venom while 
the α-neurotoxin protein makes up on 3% of the venom. The structures of the N. 
sputatrix cardiotoxin and α-neurotoxin genes were analyzed and found to be well-
conserved. However, when the promoters were characterized, it was found that, 
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despite their similarities, α-neurotoxin promoter contains a stronger silencer 
element which is responsible for reducing the amount of α-neurotoxin protein in 
the venom (Ma et al. 2001; Ma et al. 2002). Although Ma et al. 2002 describes a 
silencer element which explains how venom toxins evolve to have different 
expression levels after being duplicated from one another, it does not address the 
issue of venom gland-specific expression. Trocarin D and TrFX present a pair of 
genes which are perfect for this issue of venom gland-specific expression to be 
investigated.  
 
Although both trocarin D and TrFx have the same function and structure, 
their expression properties differ. Trocarin D has a high level of expression which 
is specific to the venom gland and TrFX has a low level of expression which is 
specific to the liver. Their gene organization reveals that the two genes are well-
conserved with differences in the promoter and intron 1 regions. The previous 
chapter has elucidated that the insertion of VERSE in the trocarin D promoter 
accounts for its elevated level of expression compared to TrFX (Kwong et al. 
2009). Therefore, it is logical to hypothesize that the differences in the intron 1 
regions of these two genes are responsible for regulating the venom gland-specific 
expression of trocarin D. Silencer elements have previously been identified within 
the intron 1 region of genes (Gaunitz et al. 2004). There are three insertions and 
two deletions in the trocarin D intron 1 region compared to TrFX. These regions 
are termed Ins1, Ins2, Ins3, Del1 and Del2 (Fig. 1.4B). This chapter aims to 
characterize the trocarin D intron 1 insertion/deletion segments for their gene 
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regulatory roles, especially tissue specific properties, using luciferase assays in 
mammalian cell lines. To my knowledge, the nature of the work within this 
chapter is the first of its kind in attempting to identify cis-elements which regulate 
venom gland-specific expression. 
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MATERIALS & METHODS 
Materials 
T. carinatus fresh liver tissues used in the genomic DNA extraction were 
supplied by Venom Supplies Pty Ltd, Tanunda, South Australia. The DNeasy 
Tissue kit was purchased from Qiagen (Valencia, CA, USA). The Long PCR 
Enzyme Mix used in the standard PCR protocol was purchased from Fermentas 
(Hanover, MD, USA). The pGEM®-T Easy vector, luciferase vectors (pGL4.10, 
pGL4.13 and pGL4.75) and Dual-GloTM Luciferase Assay System were 
purchased from Promega Corporation (Madison, WI, USA). The cell culture 
media used for cell line maintenance were purchased from Sigma (St. Louis, MO, 
USA). The FuGENE 6 transfection reagent was purchased from Roche 
Diagnostics (GmbH, Deutschland, Germany). Oligonucleotides primers were 
ordered from 1st BASE (Singapore). The ABI PRISM® BigDye® terminator 
cycle sequencing ready reaction kit was purchased from Perkin Elmer (Foster 
City, CA, USA).  
 
T. carinatus Liver Tissues and Genomic DNA Extraction 
Genomic DNA (gDNA) was extracted from T. carinatus liver tissues 
using the DNeasy Tissue kit according to the manufacturer’s instructions. For 
each extraction, 30 mg of liver tissue was taken and RNaseH was used to prevent 
RNA contamination. The gDNA integrity was examined using 0.8% agarose gel 
electrophoresis and checking its optical density. 
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Luciferase Constructs for the Characterization of the Trocarin D Intron 1 
Insertion/Deletion Segments 
Based on the gene sequence trocarin D, primers were designed to amplify 
the trocarin D intron 1 insertion/deletion segments from the T. carinatus gDNA 
using standard PCR protocols with Long PCR Enzyme Mix. While amplifying 
each intron 1 insertion/deletion segment, the five nucleotides straddling the 5’ and 
3’ end of the trocarin D intron 1 were included to preserve the intron/exon 
boundaries which are important for intron splicing (Fig. 3.1). Therefore, this 
ensures that any resulting difference in luciferase activities between the constructs 
are not due to the presence of the intron segments affecting translation. The 
various trocarin D intron 1 insertion/deletion segments are termed Ins1, Ins2, Ins3, 
Del1 and Del2 (Fig. 1.4). A scaffold/matrix-attached region (S/MAR) was 
previously predicted by bioinformatics tools within the intron 1 insertion 3 
segment (Fig. 1.4). Therefore, to investigate the gene regulatory effect of this 
S/MAR region, primers were designed to amplify this particular region (MAR). 
Likewise, the five nucleotides straddling the intron/exon boundaries of the 
trocarin D intron 1 was included.  
 
Luciferase assays indicate that silencer cis-elements might reside within 
Ins2 which is 1975 bp. Therefore, Ins2 was subdivided into three sub-segments of 
616 bp, 687 bp and 672 bp lengths. These three sub-segments were termed Ins2.1, 
Ins2.2 and Ins2.3, respectively. Ins2.2 was further sub-divided into four sub-
segments of 189 bp, 161 bp, 144 bp and 193 bp lengths. These four sub-segments 
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were termed Ins2.2.1, Ins2.2.2, Ins2.2.3 and Ins2.2.4, respectively. Likewise, the 
five nucleotides straddling the intron/exon boundaries of 5’ and 3’ end of the 
trocarin D intron 1 was included in each sub-segment.  To investigate the gene 
regulatory effect of the trocarin D intron 1 insertion/deletion segments, the 
amplified segments were concatenated behind VERSE and directionally cloned 
into the promoter-less pGL4.10 vector containing the firefly luciferase reporter 
gene. The resulting constructs are termed VIns1, VIns2, VIns3, VDel1, VDel2, 
VMAR, VIns2.1 - VIns2.3 and VIns2.2.1 - VIns2.2.4 (Fig. 3.2, 3.3 and 3.4).  
 
To confirm the presence of a silencer cis-element, the Ins2 sub-segments 
were also concatenated behind a heterologous cytomegalovirus (CMV) promoter 
and directionally cloned into the promoter-less pGL4.10 vector. The resulting 
constructs are termed CMVIns1, CMVIns2, CMVIns3, CMVDel1 and CMVDel2 
(Fig. 3.5). CMV For (5' TCGGGTACCCCTAACTGGCCTCAATATTGG 3') and 
CMV Rev (5' GCTGCTAGCCTTCTAGTGATCTGACGGTTC 3') primers were 
designed to amplify the CMV enhancer/promoter from the pGL4.75 luciferase 
vector.  
 
All constructs were verified by DNA sequencing using ABI PRISM® 
BigDye® terminator cycle sequencing ready reaction kit according to the 
manufacturer’s instructions. 
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Figure 3.1: (A) The intron/exon boundaries of the 5’ and 3’ end of the 
trocarin D intron 1. (B) The amplified trocarin D intron 1 insertion/deletion 
segment with the five nucleotides straddling the intron/exon boundaries of 
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Culture of Mammalian Cell Lines  
Luciferase constructs were transfected into three mammalian cell lines. 
CHOK1 and HepG2 cell lines were maintained in DMEM media supplemented 
with 10% fetal bovine serum and 0.1% gentamycin. HEK293T cell line was 
maintained in RPMI media supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin. All mammalian cell lines were incubated at 37 °C in a 
humidified atmosphere containing 5% CO2.  
 
Transfection and Luciferase Assays 
Cells were seeded into 96-well plates at a density of 5 x 103 cells per well. 
The mammalian cells were grown to ~70% confluency before transfection. The 
transfection efficacy was normalized by co-transfecting 750 ng of insert-pGL4.10 
firefly luciferase reporter construct with 1 ng of pGL4.73 vector containing the 
Renilla luciferase gene controlled by the SV40 promoter.  
 
Cells were transfected using FuGENE 6 transfection reagent according to 
the manufacturer’s instruction. After 24 h, luciferase activity was measured using 
the Dual-GloTM Luciferase Assay System according to the manufacturer’s 
instructions in a GloMax™ Luminometer from Promega Corporation (Madison, 
WI, USA). Relative light units were calculated by dividing the firefly luciferase 
signals by the normalizing Renilla luciferase signals.  
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Data Analysis 
All luciferase assays were performed in triplicate and luciferase assays 
were repeated at least three independent times in mammalian cell lines. The 
luciferase activity mean and standard deviation of each construct was calculated 
and represented as relative to that of VERSE promoter or CMV enhancer/promoter 
which was taken as 100%. 
 
Sequence Analysis using BLASTN and DNAMAN Softwares 
Sequence analysis was carried out for the Ins2.2.4 segment using 
BLASTN program at the National Centre for Biotechnology Information website 
(www.ncbi.nlm.nih.gov). The analysis was repeated twice, once against the whole 
NCBI database and the other against only the snake (taxid: 8570) database. The 
regions of the matching sequences are aligned together with the Ins2.2.4 sequence 
using the alignment software DNAMAN (www.lynnon.com/pc/framepc.html). 
The BLASTN identified silencer cis-element is aligned against the intron 1 of 
trocarin D and pseutarin C catalytic subunit (PCCS) using the alignment software 
DNAMAN. As the Ins2.2.2 and Ins2.2.3 segments also showed potential silencing 
activities, these segments were also briefly analyzed using the BLASTN program 
against the snake (taxid: 8570) database. 
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RESULTS 
Silencer Cis-element within Trocarin D Intron 1 Insertion 2 Segment 
To investigate the gene regulatory effect of the trocarin D intron 1 
insertion/deletion segments, these segments were concatenated behind the VERSE 
promoter (Fig. 3.2) and were used to drive the expression of the luciferase 
reporter gene. The construct was transfected into CHOK1, HepG2 and HEK293T 
cell lines. If there are silencer cis-elements present in the insertion/deletion 
segment, it would reduce the promoter activity of the VERSE promoter. This 
inhibition can be detected when the luciferase activities of the various VERSE-
Ins/Del promoter constructs are compared against that of the VERSE promoter 
construct. It is important to note that the presence of the intron segments in the 
luciferase constructs result in a longer mRNA to be synthesized. In addition to the 
luciferase gene, the RNA polymerase would also have to synthesize the 
complementary intron RNA segment. Therefore, this could lead to a lower 
efficiency in transcription which might affect luciferase expression and be 
reflected as a reduction in luciferase activity. Therefore, a silencer cis-element is 
only deemed as present within an intron segment if the reduction in relative 
luciferase activity is more than 80%. 
 
As seen from the luciferase assays, all the VERSE-Ins/Del promoter 
constructs have reduced luciferase activities compared to the VERSE promoter 
construct. The addition of the Ins/Del segments reduces VERSE promoter activity 
by 35% - 99%, 43% - 69% and 80% - 99% in CHOK1, HepG2 and HEK293T cell 
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lines, respectively (Fig. 3.2). The VERSE promoter inhibition occurs most in 
HEK293T cells while the least overall inhibition occurs in HepG2 cells. It is 
noted that VIns2, VMAR, VDel1 and VDel2 are able to reduce the VERSE 
promoter activity by more than 80% in at least one cell line. Ins2 is able to reduce 
VERSE promoter activity to 1.2%, 37.1% and 0.2% to VERSE in CHOK1, HepG2 
and HEK293T cell lines, respectively (Fig. 3.2). Del1 is able to reduce VERSE 
promoter activity to 61.5%, 31.3% and 6.0% to VERSE in CHOK1, HepG2 and 
HEK293T cell lines, respectively (Fig. 3.2). Del2 is able to reduce VERSE 
promoter activity to 29.0%, 57.1% and 1.3% to VERSE in CHOK1, HepG2 and 
HEK293T cell lines, respectively (Fig. 3.2). MAR is able to reduce VERSE 
promoter activity to 65.6%, 38.2% and 0.7% to VERSE in CHOK1, HepG2 and 
HEK293T cell lines, respectively (Fig. 3.2). This indicates that there could be 
multiple silencer cis-elements among the trocarin D insertion/deletion segments.  
 
S/MAR elements are known to have gene up-regulatory influences (Bode 
et al. 1992; Bode et al. 1995; Schubeler et al. 1996). Therefore, if there is an 
S/MAR region within Ins3, the addition of MAR would increase promoter activity 
and lead to an increase in luciferase activity. From the luciferase activities, VMAR 
has lower luciferase activities than VERSE, to 65.6%, 38.2% and 0.74% to VERSE 
in CHOK1, HepG2 and HEK293T cell lines, respectively (Fig. 3.2). Therefore, it 
is concluded that this region is not an S/MAR element.  
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Figure 3.2: Characterizing the gene regulatory role of intron 1 
insertion/deletion segments. The grey rectangle represents the VERSE promoter, 
the black blocks represent the five nucleotides which overlap the intron/exon 
boundary of trocarin D intron 1, shaded rectangles represent the intron 1 
insertion/deletion segments. Firefly luciferase genes under the control of the 
respective promoters were transfected into HepG2, HEK293T and CHOK1 cell 
lines. Renilla luciferase genes under the control of the SV40 promoter were co-
transfected as internal controls. Firefly luciferase activities of the various 
constructs were normalized against the Renilla luciferase activities and are shown 
relative to that of the VERSE promoter. The results are the mean of at least three 



















Chapter III – Identification of silencer cis-element  
within trocarin D intron 1 insertion/deletion segments 
91 
Identification of Silencer Cis-elements within Trocarin D Intron 1 Insertion 2 
Segment 
As VIns2 had the most reduction in luciferase activity, it is postulated that 
the silencer cis-elements resides within Ins2. Therefore, it was further subdivided 
into three sub-segments to narrow down the location of the silencer cis-element. It 
is observed that the addition of all three segments individually reduced VERSE 
promoter activity in the three mammalian cell lines (Fig. 3.3). This indicates that 
there could be multiple silencer cis-elements present within Ins2. It is observed 
that VIns2.2 has the lowest luciferase activities; 1.3%, 5.1% and 0.3% relative to 
VERSE in CHOK1, HepG2 and HEK293T cell lines, respectively (Fig. 3.3). 
Therefore, this suggests that the most potent silencer cis-element may reside 
within this 687 bp Ins2.2 segment. Therefore, Ins2.2 was further subdivided to 
identify the silencer cis-element. 
 
The Ins2.2 was subdivided into four sub-segments to further pinpoint the 
location of the silencer cis-element. It is observed that all four segments are able 
to significantly reduce VERSE promoter activity in the three mammalian cell lines 
(Fig. 3.4). However, VIns2.2.1, VIns2.2.2 and VIns2.2.3 had luciferase activities 
that are higher than that of VIns2.2. It is observed that VIns2.2.4 has luciferase 
activities that are lower or comparable to that of VIns2.2. The luciferase activity 
of VIns2.2.4 is 0.8%, 1.2% and 1.3% relative to VERSE in CHOK1, HepG2 and 
HEK293T cell lines, respectively (Fig. 3.4). Therefore, this indicates that the most 
potent silencer cis-element should reside in the 193 bp Ins2.2.4 segment.  
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Figure 3.3: Identification of the silencer cis-element within Ins2. The grey 
rectangle represents the VERSE promoter, the black blocks represent the five 
nucleotides which overlap the intron/exon boundary of trocarin D intron 1, shaded 
rectangles represent the intron 1 insertion/deletion segments. Firefly luciferase 
genes under the control of the respective promoters were transfected into HepG2, 
HEK293T and CHOK1 cell lines. Renilla luciferase genes under the control of the 
SV40 promoter were co-transfected as internal controls. Firefly luciferase 
activities of the various constructs were normalized against the Renilla luciferase 
activities and are shown relative to that of the VERSE promoter. The results are 
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Figure 3.4: Identification of the silencer cis-element within Ins2.2. The grey 
rectangle represents the VERSE promoter, the black blocks represent the five 
nucleotides which overlap the intron/exon boundary of trocarin D intron 1, and 
diagonally shaded rectangles represent the Ins2 sub-segments. Firefly luciferase 
genes under the control of the respective promoters were transfected into HepG2, 
HEK293T and CHOK1 cell lines. Renilla luciferase genes under the control of the 
SV40 promoter were co-transfected as internal controls. Firefly luciferase 
activities of the various constructs were normalized against the Renilla luciferase 
activities and are shown relative to that of the VERSE promoter. The results are 
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Confirmation of Silencer Cis-element using a Heterologous Promoter 
A common feature of many silencer elements is their ability to inhibit 
transcription even if they are attached to a heterologous promoter (Ogbourne and 
Antalis 1998). Therefore, to confirm the presence of the silencer cis-element, the 
Ins2.2.1-Ins2.2.4 sub-segments were concatenated to a heterologous CMV 
promoter. All the four CMVIns2.2.1 - CMVIns2.2.4 constructs had significantly 
lower luciferase activity compared to the CMV promoter (Fig. 3.5). This indicates 
that these Ins2.2 sub-segments do indeed have silencer cis-elements.  
CMVIns2.2.4 has the lowest luciferase activity which is 0.2%, 0.2%, 2.1% in 
CHOK1, HepG2 and HEK293T cell lines, respectively (Fig. 3.5). This supports 
the hypothesis that the strongest silencer cis-element resides within the 193 bp 
Ins2.2.4 intron segment.  
 
Bioinformatics Analysis of Ins2.2.4 
The BLASTN analysis was performed for the Ins2.2.4 sequence against 
the whole NCBI database. There are many matches to several organisms. 
However, only three identified sequences had 100% matches to regions within 
Ins2.2.4 (Table 3.1). The matching sequences are Homo sapiens chromosome 11, 
Mus musculus chromosome 19 and Rhesus Macaque BAC CH250-12P18. The 
accession number, identity of the matching sequences, and the region of the 
matching sequences are tabulated in Table 3.1. An alignment of the matching 
sequences to Ins2.2.4 is shown in Fig. 3.6. 
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Figure 3.5: Identification of the silencer cis-element within Ins2. The 
vertically striped rectangle represents the CMV promoter, the black blocks 
represent the five nucleotides which overlap the intron/exon boundary of trocarin 
D intron 1, and diagonally shaded rectangles represent the intron 1 
insertion/deletion segments. Firefly luciferase genes under the control of the 
respective promoters were transfected into HepG2, HEK293T and CHOK1 cell 
lines. Renilla luciferase genes under the control of the SV40 promoter were co-
transfected as internal controls. Firefly luciferase activities of the various 
constructs were normalized against the Renilla luciferase activities and are shown 
relative to that of the VERSE promoter. The results are the mean of at least three 
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Table 3.1: BLASTN analysis of Ins2.2.4 against NCBI database. Only 100% matches are listed. 
 






1 AC087373.4 Homo sapiens chromosome 11, clone RP11-54J7, complete sequence Repeat region 100% 
2 AC115771.13 Mus musculus chromosome 19, clone RP23-116D4, complete sequence Repeat region 100% 
3 AC169699.1 Rhesus Macaque BAC CH250-12P18 (Children's Hospital Oakland Research Institute Rhesus macaque Adult Male BAC Library) complete sequence ? 100% 
 
Table 3.2: BLASTN analysis of Ins2.2.4 against snake taxonomy (taxid: 8570) database. Only 100% and 
shortlisted matches are listed. 
 






1 dbj|AB525144.1|  Elaphe quadrivirgata EQOR16 gene for olfactory receptor, partial cds Coding Region 
2 dbj|AB525118.1| Naja kaouthia NKOR10 gene for olfactory receptor, partial cds Coding Region 
3 dbj|AB524696.1|  Laticauda laticaudata LLOR2 gene for olfactory receptor, partial  Coding Region 
4 gb|GQ196832.1|  Agkistrodon contortrix clone E33DIFJ02G3DAK microsatellite sequence ? 
5 gb|GQ191351.1| Agkistrodon contortrix clone E33DIFJ02G7WYI microsatellite sequence ? 
6 gb|GQ195582.1| Agkistrodon contortrix clone E33DIFJ02JXDL2 microsatellite sequence ? 
7 gb|GQ190896.1| Agkistrodon contortrix clone E33DIFJ02FJFJ8 microsatellite sequence ? 
8 gb|GQ187143.1|  Agkistrodon contortrix clone E33DIFJ02ITOTK microsatellite sequence ? 
9 gb|GQ184850.1|  Agkistrodon contortrix clone E33DIFJ02FIR7B microsatellite sequence ? 
10 dbj|AB003473.1| Trimeresurus flavoviridis DNA for phospholipase A2 inhibitor, complete cds Promoter region 
100% 
11 dbj|AB062440.1|  Laticauda semifasciata pla2 gene for phospholipase A2, complete cds Intron 1 
12 gb|AB062439.1 Laticauda semifasciata pla2 gene for phospholipase A2, complete cds Intron 1 88% 
13 AB062442.1 Laticauda laticaudata pla2 gene for phospholipase A2, complete cds Intron 1 78% 
14 |AB062441.1 Laticauda laticaudata pla2 gene for phospholipase A2, complete cds Intron 1 78% 
15 AB062448.1| Laticauda colubrina pla2 gene for phospholipase A2, complete cds Intron 1 82% 
16 gb|AF101236.1| Naja sputatrix neutral phospholipase A2 (NPLA2) gene, complete cds Intron 1 
17 gb|AF101235.1|  Naja sputatrix acidic phospholipase A2 (APLA2) gene, complete cds Intron 1 78% 
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The BLASTN analysis was repeated for the Ins2.2.4 sequence against the 
snake database (taxid: 8570). Besides the 100% matches, matches to enzymes are 
complied in Table 3.2 which tabulates the accession number, identity of the 
matching sequences, and the region of the matching sequences. It is observed that 
the matches to the olfactory receptor gene of Elaphe quadrivirgata, N. kaouthia 
and Laticauda laticaudata lie within their coding region. Hence, these regions 
within these genes should have no gene regulatory properties. The matches to 
Agkistrodon contortrix belong to microsatellite sequences and have not been 
characterized (TODD A.CASTOE et al. 2010). Interestingly, Ins2.2.4 matches to 
the promoter region of the Trimeresurus flavoviridis phospholipase A2 (PLA2) 
inhibitor, and the intron 1 region of the L. semifasciata, L. laticaudata, L. 
colubrina and N. sputatrix PLA2, respectively (Table 3.2). An alignment of the 
matching sequences to Ins2.2.4 is shown in Fig. 3.6. From the alignment, it is 
observed that there is a 26 bp consensus sequence of “AGA(A/G)AG(T/A)GG 
A(A/G)AT(T/A)AAGAGA(A/T)A(G/A)AGG”. This region is common among 
the matching Laticauda and Naja species PLA2 intron 1 sequences. 
 
Based on the BLASTN and alignment analysis, the silencer cis-element 
could reside between 122-147 nucleotides within Ins2.2.4 (Fig. 3.6). It was 
investigated if such a silencer cis-element could be present within the PCCS gene. 
Like trocarin D, PCCS has evolved by gene duplication and accelerated evolution 
from its FX counterpart, PFX. Similar to trocarin D intron 1, PCCS intron 1 has 
three major insertions and two major deletions when compared to PFX. When 
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compared with trocarin D, both venom prothrombin activators have similar insert 
sizes and these inserts are inserted at identical sites (Honors thesis 2007, Pang Shu 
Yi). The trocarin D Ins2 is 1975 bp compared to the PCCS intron 1 insert two 
which is 1965 bp. The Ins2.2.4 silencer cis-element was aligned against the 
trocarin D and PCCS intron 1 insertion 2 segment (Fig. 3.7). Trocarin D Ins2 
shows a 1222 bp overlap with that of PCCS. Within this overlap, there is a match 
found within PCCS to the 26 bp trocarin D silencer cis-element. 23 out of the 26 
nucleotides are identical. There are no matches found when these 26 nucleotides 
were aligned with the intron 1 of PFX. 
 
 As Ins2.2.2 and Ins2.2.3 segments also showed strong silencer activities, 
these segments were also briefly analyzed using BLASTN bioinformatics tools. 
Looking at those BLASTN observed matches which resided in non-coding 
regions, both Ins2.2.2 and Ins2.2.3 segments showed regions of similarities which 
reside in other snake venom toxin intron 1 regions. The Ins2.2.2 segment shows 
regions of similarities to the intron 1 regions of P. textilis alpha neurotoxin 
isoforms (AF204969.1, AF204973.1, AF204972.1, AF204971.1 and 
AF204970.1). The Ins2.2.3 segment shows regions of similarities to the intron 1 
regions of P. textilis alpha neurotoxin isoforms (AF204969.1, AF204973.1, 
AF204972.1, AF204971.1 and AF204970.1), and Bungarus multicinctus 
A1/A2/A8 chain of beta-bungarotoxin (AJ431709.1, AJ431707.1, AJ431708.1). 
Together with the results shown from the bioinformatics analysis of the Ins2.2.4 
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segment, the intron 1 region of snake venom toxins is highlighted as a potential 
regulator of tissue-specific expression. 
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DISCUSSION 
In this chapter, the trocarin D intron 1 insertion/deletion segments are 
characterized for their gene regulatory properties, particularly venom gland-
specific expression, using luciferase assays in mammalian cell lines. From the 
initial screening, it is noticed that all the trocarin D intron 1 insertion/deletion 
segments show reduction in luciferase activities. This indicates that there is an 
inhibition of the VERSE promoter activity when the segments are individually 
added. However, it is noted that Ins1 and Ins3 do not significantly reduce 
luciferase activity, i.e. not more than 80%. Hence, if there are any silencer cis-
elements present within these two segments, these are probably not the main 
regulators but rather might serve to fine-tune the tissue specific expression 
property.  
 
VDel1 and VDel2 show significant reduction in luciferase activities in 
HEK293T cells. Hence, there should be silencer cis-elements present within the 
Del1 and Del2 segments. However, as these two segments are not present within 
the trocarin D gene, these silencer cis-elements should not have any role in 
controlling venom gland-specific expression. These segments which are present in 
the TrFX gene might be responsible for its liver-specific expression. Therefore, 
their removal from the trocarin D duplicated twin gene has allowed it to be 
expressed in a tissue outside the liver. However, this is beyond the scope of this 
chapter which aims to characterize silencer cis-elements which control the venom 
gland-tissue specific expression. VMAR also shows a significant reduction of 
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luciferase activities in HEK293T cells. However, before it is concluded that MAR 
contains any silencer cis-elements, it must be noted that its luciferase results are in 
contradiction to that of the VIns3 construct. As MAR is a subset of Ins3, its 
inhibitory effect should not be more than that of Ins3. The reason for this increase 
of MAR inhibitory effect is not known. This leaves Ins2 as the only segment 
which shows potential silencing activity. Hence, it was further characterized for 
its silencer cis-elements. 
 
As Ins2.2.1-Ins2.2.4 intron segments are able to significantly reduce the 
activity of the VERSE and CMV promoter, it suggests that there are multiple 
silencer cis-elements present within Ins2.2 which is 687 bp. Luciferase assays 
further identifies Ins2.2.4 (193 bp) as the region having the most potent venom 
gland-specific silencer cis-element. The characterization work described in this 
chapter has been successful in localizing the tissue specific cis-element from a 
region of 1975 bp to 193 bp. Bioinformatics tools were employed to investigate if 
this trocarin D venom gland-specific silencer cis-element is present in other 
venom toxins and could possibly regulate their venom gland-specific expression. 
Although it is not a 100% match, it was found that a 26 bp region within Ins2.2.4 
is also present in the intron 1 region of other snake venom PLA2 enzymes. This 
region is also present within the intron 1 of P. textilis PCCS gene which is a group 
C prothrombin activator.  
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In terms of understanding the venom gland-specific expression, the results 
here reveal that the intron 1 region of the toxin genes are important and the 
bioinformatics analysis of Ins2.2.4 has even localized the silencer cis-element to a 
26 bp region. Taking PCCS and trocarin D as respective representatives of group 
C and D prothrombin activators, and the matching PLA2 sequences, we can 
identify with confidence the silencer cis-elements which are responsible for the 
tissue-specific expression of these groups of toxins. As more venom toxin genes 
are being described, focus can be given to their intron 1 region to investigate if a 
similar silencer cis-element is present. However, there are other available venom 
toxin genes whose intron 1 region shows no homology to this 26 bp segment. As 
venom toxins are a diverse group of enzymes with recruited independently 
multiple times, it is not surprising that this silencer cis-element is by no means the 
only one of its kind.  
 
Two limitations of the results presented in this chapter are that (1) the 26 
bp silencer element has been pinpointed within the Ins2.2.4 (193 bp) segment 
only by bioinformatics analysis, and (2) this silencer cis-element has only been 
shown to reduce promoter activity in non-venom gland cells. A luciferase 
construct consisting of the VERSE promoter concatenated to the 26 bp silencer 
cis-element needs to be made and tested for its tissue-specific expression property. 
Also, luciferase assays needs to be conducted using venom gland cells to proof 
that the silencer cis-element is indeed venom gland-specific. In this case, if this 
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cis-element is indeed a venom gland specific, it should be able to allow VERSE 
promoter activity and luciferase activity will be detected.  
 
This thesis first set out to understand how genetic differences between 
trocarin D and TrFX are responsible for altering gene expression from a low and 
liver-specific expression to one that is high and venom gland-specific. In the 
previous chapter, the cis-elements responsible for the elevated level of expression 
have been identified within the trocarin D VERSE promoter region. From this 
chapter we identified the cis-element within the trocarin D intron 1 region that is 
responsible for tissue-specific expression. The results of both chapters have 
allowed us to understand the molecular elements which are responsible for the 
recruitment of blood coagulation factor proteins into the venom genome as venom 
prothrombin activators. The following chapter will attempt to move into the next 
domain of proteomics to identify the interacting trans-factors that play a role in 
this venom recruitment. 
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INTRODUCTION 
With regards to establishing the regulatory network of a gene, the characterization 
of regulatory cis-elements only provides partial information. As mentioned in chapter 1, 
regulatory cis-elements interact with trans-factors which are key determinants of whether 
the transcription of a gene is activated or repressed. As all cells within an organism 
contain the same set of genes, the presence or availability of the necessary trans-factors is 
one mechanism in which cells regulate tissue-specific gene expression. Therefore, to 
establish the complete transcriptional regulatory network, it is essential to identify the 
corresponding trans-factors and how they interact with each other and with the cis-
elements to result in the overall transcription outcome.  
 
 As described in Chapter 2, we have characterized the cis-elements within the 
trocarin D VERSE promoter element which are responsible for the elevated level of 
expression of trocarin D. Besides the cis-elements that have already been well-
characterized (i.e. TATA, GATA and Y box binding proteins), there are three novel cis-
elements (Sup, Up1 and Up2) that have been identified within the VERSE promoter. The 
luciferase assays have indicated that these three cis-elements play certain roles in 
influencing the promoter activity of VERSE, and that Sup and Up2 work synergistically 
together. As these three cis-elements are novel, their interacting trans-factors could also 
be novel. Therefore, the identification and characterization of these novel trans-factors 
would add valuable information regarding transcription factors. However, if the 
interacting trans-factor has already been identified and characterized, Sup, Up1 or Up2 
cis-elements would present a new binding motif which will contribute to the further 
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characterization of the trans-factor. Lastly, the identification of the Sup and Up2 trans-
factors may help towards understanding how they interact and work synergistically 
towards the overall VERSE promoter activity. Therefore, it would be interesting to 
identify the trans-factors that bind and interact with the novel Sup, Up1 and Up2 cis-
elements. 
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MATERIALS & METHODS 
Materials 
The RPMI cell culture media was purchased from Sigma (St. Louis, MO, USA). 
The Nuclear Extraction Kit was purchased from Active Motif (Carlsbad, CA, USA). 
DNA probes used in the electrophoretic mobility shift assay and DNA-affinity 
chromatography were ordered from 1st BASE (Singapore). The LightShift® 
Chemiluminescent EMSA Kit was purchased from PIERCE (Rockford, IL, USA). The 
Pfu DNA polymerase used in the self-priming PCR for the concatenation of probes in the 
DNA-affinity chromatography was purchased from Fermentas (Hanover, MD, USA). The 
DNA-binding Protein Purification Kit was purchased from Roche Diagnostics (GmbH, 
Deutschland, Germany). 
 
Extraction of Nuclear Proteins from HEK293T Cells 
HEK293T cell line was maintained in RPMI media supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin. The cells were incubated at 37 °C in a 
humidified atmosphere containing 5% CO2. Nuclear protein extract was harvested from 
approximately 8.8 x 106 HEK293T cells using the Nuclear Extraction Kit. The 
concentration of nuclear protein extract was quantified using the NanoVue Plus 
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Electrophoretic Mobility Shift Assay (EMSA) to Detect Trans-factor Interaction 
with Novel Sup, Up1 and Up2 Cis-elements 
5’ biotin labeled DNA forward oligo primers were designed based on the 
sequence of the three novel cis-elements (Sup, Up1 and Up2) identified in chapter 2. 
These oligos are termed bio-Sup, bio-Up1 and bio-Up2. The Sup and Up1 cis-elements 
contain Y box consensus sequence (ATTGG) that was not previously identified by 
bioinformatics tools. Therefore, to determine that any shifts detected in the Sup and Up1 
oligos were not due to interactions with the binding of Y box proteins, EMSA was 
performed using Sup and Up1 oligos which had their Y box consensus sequence mutated. 
These mutated oligos are termed bio-Sup- and bio-Up1- . Double-stranded biotin labeled 
DNA probes were produced by first mixing the 5’ biotin end-labeled forward primers 
with their complementary reverse primer at a 1:1 molar ratio, and annealing them by 
heating the mixture up to 95 °C for 5 min and letting it cool at -1 °C/min till room 
temperature.  
 
EMSA was performed by mixing 2 μM of 5’ biotin oligos with 10 μg of 
HEK293T nuclear protein extract in binding buffer (100 mM Tris, 500 mM KCl, 10 mM 
DTT; pH 7.5). 1 μg of Poly (dI•dC) was added to the binding reaction to reduce 
nonspecific binding. Competitive binding assays were also performed by adding 50 μM 
of non-biotinylated competitor oligos (25X concentration) to the binding reaction. The 
binding reactions were incubated in room temperature for 30 min before being run on a 
4% polyacrylamide gel in 0.5X TBE buffer at 100 V for one hour. The binding reactions 
were subsequently transferred by electrophoresis to a nylon membrane at 100 V for one 
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hour in a cold room. The nylon membrane was removed and excess buffer was absorbed. 
The binding reactions were then cross-linked to the nylon membrane using a UV-light 
cross linker instrument. The position of the 5’ biotin oligos were then detected using the 
streptavidin-horseradish peroxidase conjugate and chemiluminescence substrate which 
are provided in the LightShift® Chemiluminescent EMSA kit. The chemiluminescence 
was then captured onto an X-ray film and developed. 
 
Purification of Interacting Trans-factor by DNA Affinity Chromatography 
5’ phosphorylated forward primers were designed based on the sequence of the 
three novel cis-elements (Sup, Up1 and Up2) identified in chapter 2. Instead of having a 
single protein-binding oligo to “trap” the nuclear trans-factor, the oligos were 
concatenated to form a long oligo with many direct repeats. This increases the binding 
capacity as it allows more binding sites on the probe for the nuclear protein to interact. 
To obtain these long concatenated oligos, the 5’ phosphorylated forward primers were 
self-primed with complementary reverse primers using standard PCR techniques with Pfu 
DNA polymerase. The long concatenated oligo was then ligated using T4-DNA ligase 
through its 5’ phosphorylated ends to the 3’ end of a tethered oligonucleotide, which is 
provided by the DNA-binding Protein Purification Kit. This tethered oligonucleotide is 
end labeled by a 5’ biotin molecule which is then attached to a streptavidin magnetic 
particle. This complex of the long concatenated oligo and the tethered oligonucleotide is 
termed as the protein-binding oligo/magnetic particle complex. 
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To purify the interacting trans-factors, the protein-binding oligo/magnetic particle 
complexes were mixed with 50 μg of HEK293T nuclear protein extract. Poly (dI•dC) (1 
μg/μl) was also added to reduce nonspecific trans-factor binding. Washing was carried 
out with reagents provided by the DNA-binding Protein Purification Kit on a magnetic 
plate. As specific trans-factors have a stronger interaction with the oligo than non-
specific trans-factors, a gradient potassium chloride (KCl) salt concentration (0.5 M, 1.0 
M, 1.5 M and 2.0 M) was used to elute the trans-factor which bound to the oligos. 
Therefore, the proteins which are in the 2.0 M salt eluate are deemed as the most specific 
trans-factors and are used for protein identification. All reagents except the primers and 
Pfu DNA polymerase were provided by the DNA-binding Protein Purification Kit. 
 
The four KCL salt eluates and the supernatant from the last washing step were 
analyzed on a SDS polyacrylamide gel with a concentration gradient of 4-20%. The 
protein bands were subsequently visualized by silver staining. 
 
Identification of Purified Trans-factor by Matrix-Assisted Laser 
Desorption/Ionization Time Of Flight/Time Of Flight (MALDI/TOF-TOF)  
The proteins were extracted from the protein bands by dissolving in a solution 
that contained 0.1% v/v trifluoroacetic acid (TFA) and 50% v/v acetonitrile (ACN). 
Subsequently, 0.5 μl of extracted proteins were spotted on a 384 well target plate and 
crystallized with 0.5 μl of matrix solution (10 mg/ml). The matrix solution was a 
saturated solution which consisted of α–cyano-4-hydroxycinnamic acid (CHCA) in 0.1% 
v/v TFA and 50% v/v ACN.  
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The samples were then analyzed on the 4800 Proteomics Analyzer Matrix-
Assisted Laser Desorption/Ionization Time-Of-Flight/Time-Of-Flight (MALDI/TOF-
TOF) (Applied Biosystems). Mass spectrometry (MS) data was automatically acquired in 
the reflectron mode by using the Reflectron Method which consisted of the exclusion list 
for most-common trypsin and keratin peaks. Consequently, ten most intense ions from 
Peptide Mass Fingerprinting (PMF) data were selected for further MS/MS fragmentation 
and analysis. The collision energy of the MS system was set at 1 kV and the collision gas 
used was nitrogen. 
 
Protein identification was obtained by submitting MS and MS/MS data to the 
database search engine, MASCOT v 2.1 (Matrix Science Ltd., London, UK). An MS data 
search was conducted by using NCBI Database with the following parameter setting: 
Homo sapiens taxonomy; mass error tolerance of 100 ppm for MS data and 0.4 Da for 
MS/MS data; carbamidomethylation of cysteine for fixed modification and methionine 
oxidation for variable modification. For the purpose of data interpretation, GPS Explorer 
Software v 4.9 (Applied Biosystems) was used for the further analysis. 
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RESULTS 
Interaction of Trans-factor with Novel VERSE Cis-elements 
EMSA was performed to investigate if the three novel VERSE cis-elements (Sup, 
Up1 and Up2) interact with any trans-factors. As the VERSE characterization showed 
similar trends in all three cell lines (HepG2, HEK293T and CHOK1), nuclear proteins 
were chosen to be extracted from HEK293T cell lines. 5’ biotin oligos were designed 
based on the sequences of the three novel cis-elements. These probes were individually 
incubated with the HEK293T nuclear proteins and ran on a gel. The positions of the 5’ 
biotin oligos were detected using chemiluminescence. If any trans-factor interacted with 
these oligos, it would form a protein/oligo complex and retard the migration of the 5’ 
biotin oligo on the gel. Therefore, this retardation would be reflected in a positional shift 
when compared to the free 5’ biotin oligo. A competitive assay was also performed by 
adding a non-biotinylated oligo to the binding reaction mixtures to investigate if the 
interaction between the trans-factor and the oligo is specific. If the interaction is specific, 
the non-biotinylated oligo will compete with the biotinylated oligo for binding to the 
trans-factor protein. Hence, the intensity of the band representing the protein/oligo 
complex will either decrease or disappear. 
 
Results of EMSA show that all three novel VERSE cis-elements (Sup, Up1 and 
Up2) interact individually with trans-factors (Fig. 4.1). When the HEK293T nuclear 
protein extract was added to the 5’ biotin Sup oligo, there is a distinct positional shift 
observed (Fig 4.1, Lane 2) and this band disappears (Fig 4.1, Lane 3) when a competitive 
non-biotinylated Sup oligo is added. This indicates that trans-factor binding to the Sup 
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cis-element is specific using a 25X competition level. When nuclear protein extract was 
added to the 5’ biotin Up1 oligo, there are two bands which represent positional shifts of 
the biotinylated Up1 oligo (Fig. 4.1, Lane 5). However, only one band disappears when 
the competitor non-biotinylated Up1 oligo is added. This band (Fig. 4.1, Lanes 5 and 6, 
red box) corresponds to the binding of a specific trans-factor. The other positional shift 
band which is present in both lanes 5 and 6 is a result of non-specific trans-factor binding. 
Therefore, using a level of 25X competition, this shows that binding of trans-factors to 
the Up1 cis-element is both specific and non-specific. When nuclear protein extract was 
added to the 5’ biotin Up2 oligo, there is a band and smearing which indicates a 
positional shift of the biotinylated Up2 oligo. However, this band and smearing are a 
result of non-specific trans-factor binding as they are still present when the competitor 
Up2 oligo is added (Fig. 4.1, Lane 9). Therefore, using a level of 25X competition, this 
indicates that trans-factor binding to the Up2 cis-element is non-specific. 
 
EMSA was performed using mutated 5’ biotin Sup and Up1 oligos (bio-Sup- and 
bio-Up1-) to confirm that the bindings observed are not due to interactions with the Y box 
protein (Fig. 4.1, Lanes 10 – 15). It is observed that the binding patterns are similar to 
that of the unmutated oligos. This shows that the Y box protein does not interact with 
both Sup and Up1 cis-elements. Since there are no binding pattern changes despite the Y 
box consensus sequence mutation, it suggests that the Y box consensus sequence within 
both these cis-elements are nonfunctional and do not interact with Y box binding proteins. 
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Purification of Trans-factor by DNA-affinity Chromatography 
The HEK293T nuclear trans-factors that bound to the novel VERSE oligos were 
purified using DNA-affinity chromatography. The oligo sequences which were used to 
capture the trans-factors are identical to those used in the EMSA. The KCL salt eluates 
and the supernatant from the last washing step were then run on a gradient of 4-20% SDS 
polyacrylamide gel. The protein bands were visualized using a silver staining protocol. 
 
The Sup DNA-affinity chromatography profile shows four dominant protein 
bands which were present in all the 1.0, 1.5 and 2.0 M salt eluates (Fig. 4.2). The protein 
bands in the 2.0 M salt eluate were used for protein identification. The 0.5 M salt eluate 
had many protein bands and it serves to remove unspecific trans-factor which bound to 
the oligo. Both the Up1 and Up2 DNA-affinity chromatography profiles show numerous 
bands in all the salt eluates. There are eight and ten dominant protein bands in the Up1 
and Up2 2.0 M salt eluates, respectively (Fig. 4.3). As the EMSA results previously 
indicate that Up1 and Up2 oligos interact with both specific and non-specific trans-
factors, it is not surprising that many proteins are still eluted despite repeated washing 
with many salt concentrations. All the dominant protein bands in the Up1 and Up2 2.0 M 
salt eluates were sent for protein identification so that specific trans-factors may still be 
identified. Similarly, the 0.5 M salt eluate in both Up1 and Up2 profiles show more 
protein bands and it serves to remove unspecific trans-factor which bound to the oligos. 
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1. Keratin (66 kDa)
2. TNS1 protein (47 kDa)
3. POU domain, class 6, 
transcription factor 1 (32 kDa)
4. POU domain, class 6, 
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Figure 4.3: Silver staining of the DNA-affinity chromatography purified trans-factors that bind to the 
Up1 and Up2 oligo. 
B. DNA-affinity chromatography using Up2 oligo
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Identification of Purified Trans-factors using MALDI/TOF-TOF 
 
Identification of proteins captured by the Sup oligo 
Four dominant protein bands were excised from the 2.0 M salt eluate from the 
Sup DNA-affinity chromatography. Base on the protein marker in the gel, these protein 
bands are estimated to be 60 kDa, 50 kDa, 37 kDa and 35 kDa (Fig. 4.2). These protein 
bands are excised and subjected to MALDI-TOF/TOF analysis. 
 
The 60 kDa protein was identified as keratin (gi|11935049) which has a mass of 
66198 Da. The sequence coverage of the purified protein against the keratin protein is 
23%. Keratin is most possibly pulled down as a contaminant during DNA-affinity 
chromatography sample preparation. Repeated purifications were unable to remove this 
contamination. The 50 kDa protein is identified as TNS1 protein (gi|40225452) which has 
a mass of 47282 Da. The sequence coverage of the purified protein against the TNS1 
protein is 33%. The TNS1 protein, also known as tensin, which is a cytoplasmic 
phosphoprotein that is localized to integrin-mediated focal adhesions (Lo 2004). It binds 
to actin filaments and contains a phosphotyrosine-binding (PTB) domain, which interacts 
with the cytoplasmic tails of β integrin. This purified protein is probably a cytoplasmic 
contamination during the extraction of the nuclear proteins. As both keratin and TNS1 
protein have no transcriptional regulatory properties, they are considered as contaminants. 
 
The 37 kDa and 35 kDa proteins were both identified as POU class 6 homeobox 1 
(gi|223890225) which has a mass of 32796 Da. Eight polypeptides from the PMF of the 
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37 kDa protein show significant homology to the POU class 6 homeobox 1 (Fig. 4.4A). 
These polypeptides form sequence coverage of 23% against the POU class 6 homeobox 1 
protein sequence (Fig. 4.4B).  However, as the PMF spectrum has a range of 799.0 - 
4013.0 Da, there are only 11 possible polypeptides (127 residues) that are identifiable 
from the trypsin digest of the protein (Fig. 4.4B). Out of these 11 possible polypeptides, 
six of these polypeptides (81 residues) could be identified in the PMF (Fig. 4.4B). 
Therefore, the possible sequence coverage identified is actually 81 out of 127 residues 
(64%). During the MASCOT search for each protein, a score is calculated using a Mowse 
algorithm to determine if the observed match is a random event (p < 0.05). The cut off 
score for any observed match to be significant and non-random is 64. The POU class 6 
homeobox 1 observed match had a score of 307. 
 
Four polypeptides from the PMF of the 35 kDa protein show significant 
homology to the POU class 6 homeobox 1 (Fig. 4.5A). These polypeptides form 
sequence coverage of 17% against the POU class 6 homeobox 1 protein sequence (Fig. 
4.5B). However, as the PMF has a range of 799.0 - 4013.0 Da, there are only 11 possible 
polypeptides (127 residues) that are identifiable from the trypsin digest of the protein (Fig. 
4.5B). Out of these 11 possible peptides, four of these peptides (54 residues) could be 
identified in the PMF (Fig. 4.5B). Therefore, the possible sequence coverage identified is 
in fact 54 out of 127 residues (43%). The cut off score for any observed match to be 
significant and non-random is 64. The POU class 6 homeobox 1 observed match had a 
score of 76. 
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The POU class 6 homeobox 1 protein has been documented to have 
transcriptional regulatory properties and shown to bind AT-rich motifs. The classical 
binding motif of class 1 POU transcription factors is ATGCAAAT. However, class 6 
POU transcription factors have been shown to be capable of binding to other AT-rich 
motifs. Although Sup cis-element (TTGGACAGATACC) does not match to any of these 
previously identified AT-rich motifs, it has a high percentage of AT nucleotides (7 out of 
13). Therefore, the class 6 POU transcription fact is concluded to be a potential Sup 
trans-factor. 
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No. Experimental Mass  
Theoretical 
Mass Peptide Sequence  
Residues of 
Observed Matched Protein Matched 
1 809.45 808.37   ELNYDR 270 - 275 
2 881.39   880.40   VWFCNR 280 - 285 
3 1292.63   1291.65   ELNYDREVVR 270 - 279 
4 1929.89   1928.95   TSFTPQAIEALNAYFEK 239 - 255 
5 2007.84   2006.90   NQEGQQNLMEFVGGEPSK + Oxidation (M) 216 - 233 
6 2135.92   2135.00   NQEGQQNLMEFVGGEPSKK + Oxidation (M) 216 - 234 
7 3021.44   3020.52   LSLGLTQTQVGQALTATEGPAYSQSAICR 159 - 187 
8 3177.52  3176.62   RLSLGLTQTQVGQALTATEGPAYSQSAICR 158 - 187 





B.       
     1 MPGISSQILT NAQGQVIGTL PWVVNSASVA APAPAQSLQV QAVTPQLLLN  
 
    51 AQGQVIATLA SSPLPPPVAV RKPSTPESPA KSEVQPIQPT PTVPQPAVVI  
 
   101 ASPAPAAKPS ASAPIPITCS ETPTVSQLVS KPHTPSLDED GINLEEIREF  
              7/8 
   151 AKNFKIRRLS LGLTQTQVGQ ALTATEGPAY SQSAICRFEK LDITPKSAQK  
                       5/6                      4 
   201 LKPVLEKWLN EAELRNQEGQ QNLMEFVGGE PSKKRKRRTS FTPQAIEALN  
                           1/3        2 
   251 AYFEKNPLPT GQEITEIAKE LNYDREVVRV WFCNRRQTLK NTSKLNVFQI  
 
   301 P 
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Fig. 4.4: A. Peptide mass fingerprinting (PMF) of the 37 kDa protein from the Sup DNA-affinity chromatography profile. A. 
Sequence coverage of the polypeptides against POU class 6 homeobox 1 (gi|223890225). PMF polypeptide are numbered and 
their residues are bolded and underlined, the possible polypeptides produced by trypsin digest within 799.0 – 4013.0 Da are 
highlighted alternately by either yellow or green. C. The spectrum of the PMF. 
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No. Experimental Mass 
Theoretical 
Mass Peptide Sequence 
Residues of 
Observed Matched Protein Matched 
1 881.39 808.37 VWFCNR 280 - 285 
2 2007.83 2006.82 NQEGQQNLMEFVGGEPSK + Oxidation (M) 216 - 233 
3 2135.92 2134.92 NQEGQQNLMEFVGGEPSKK + Oxidation (M) 216 - 234 
4 3021.43 3020.42 LSLGLTQTQVGQALTATEGPAYSQSAICR 159 - 187) 






      
     1 MPGISSQILT NAQGQVIGTL PWVVNSASVA APAPAQSLQV QAVTPQLLLN  
 
    51 AQGQVIATLA SSPLPPPVAV RKPSTPESPA KSEVQPIQPT PTVPQPAVVI  
 
   101 ASPAPAAKPS ASAPIPITCS ETPTVSQLVS KPHTPSLDED GINLEEIREF  
               4 
   151 AKNFKIRRLS LGLTQTQVGQ ALTATEGPAY SQSAICRFEK LDITPKSAQK  
                       2/3 
   201 LKPVLEKWLN EAELRNQEGQ QNLMEFVGGE PSKKRKRRTS FTPQAIEALN  
              1 
   251 AYFEKNPLPT GQEITEIAKE LNYDREVVRV WFCNRRQTLK NTSKLNVFQI  
 
   301 P 
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Fig. 4.5: A. Peptide mass fingerprinting (PMF) of the 35 kDa protein from the Sup DNA-affinity chromatography profile. A. 
Sequence coverage of the polypeptides against POU class 6 homeobox 1 (gi|223890225). PMF polypeptide are numbered and 
their residues are bolded and underlined, the possible polypeptides produced by trypsin digest within 799.0 – 4013.0 Da are 
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Identification of proteins captured by the Up1 and Up2 oligos 
The protein bands excised from the 2.0 M salt eluates of both the Up1 and 
Up2 DNA-affinity chromatography were not identifiable as their concentrations 
were too low. The protein identity matches generated from the NCBI database for 
the excised proteins were all scored as random and insignificant. 
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DISCUSSION 
The EMSA results show that Up1 and Up2 oligos interact both 
specifically and non-specifically with nuclear proteins. Purification by DNA-
affinity chromatography did not yield sufficient concentration for the proteins to 
be identifiable by MALDI/TOF-TOF. Therefore, the trans-factors which interact 
with Up1 and Up2 cis-elements cannot be identified. From the Sup DNA-affinity 
chromatography profile, the proteins purified were identified as keratin, TNS1 
protein and POU class 6 homeobox 1. It is concluded that keratin and TNS1 
proteins are products of contamination, and that the trans-factor that interacts with 
the Sup cis-element is potentially POU class 6 homeobox 1 which belongs to the 
POU family, class 6, transcription factor (POU6F). The following section will 
describe the structural and functional characteristics of POU transcription factors 
and its class 6 members. Subsequently, it will be concluded how the POU6F 
transcription factors could potentially be the trans-factor which binds to the Sup 
cis-element. 
 
POU Transcription Factor 
The first three members of this transcription factor family identified were 
the Pituitary-specific transcription factor Pit-1 and the Octamer transcription 
factor proteins Oct-1 and Oct-2 of mammals, and the neural Unc-86 of 
Caenorhabditis elegans. The acronym POU was derived from first letters of these 
proteins (Herr et al. 1988). The three mammalian proteins have transcriptional 
regulatory properties, and unc-86 is a cell lineage and cell differentiation gene. 
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POU domain genes have been described in organisms as divergent as 
Caenorhabditis elegans, Drosophila, Xenopus, zebrafish and human, but have not 
yet been identified in plants and fungi (Ilia 2004). 
 
Structurally, the POU family is defined by a bipartite DNA-binding, which 
consists of a N-terminal POU-specific (POUS) subdomain which is approximately 
80 amino-acids residues and a C-terminal POU-homeobox (POUH) subdomain 
which is approximately 60 amino-acid residues (Botfield et al. 1992; Ingraham et 
al. 1990; Sturm and Herr 1988). Both these domains are needed for specific DNA 
binding. The POUS and POUH subdomains are joined by a 15–57 amino-acid 
linker. The structures of complexes including both POU subdomains bound to 
DNA have been determined (Assa-Munt et al. 1993; Cox et al. 1995; Jacobson et 
al. 1997; Klemm et al. 1994). Many other members of this transcription factor 
family have been identified and they have been divided into six classes based on 
amino acid sequence of the linker region and the POUH subdomain (Wegner et al. 
1993).  
 
Functionally, POU proteins are transcription factors which are involved in 
a wide variety of biological processes, such as embryonic stem cell differentiation 
and development of highly specialized tissues. Although they are abundantly 
found in the central nervous systems, they are also found in other tissues (Ryan 
and Rosenfeld 1997). They interact with the promoter region of genes by 
specifically binding to the classical DNA octamer motif ATGCAAAT. While the 
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POUH subdomain is related to the DNA-binding homeodomain of other 
transcription factors, the POUS subdomain is unique to the POU transcription 
factor family and it is the domain which gives rise to the function of the POU 
transcription factor (Wegner et al. 1993). 
 
Class 6 POU transcription factor (POU6F) 
The brain-5 protein (Brn-5) from the rat brain is first member of the 
POU6F proteins that was identified (Andersen et al. 1993). Like most of the other 
POU protein classes, Brn-5 is most abundant in the developing brain and spinal 
cord after early days of embryogenesis, and in the adult brain (Andersen et al. 
1993). However, Brn-5 is also found to be expressed in multiple tissues outside 
the central nervous system, including kidney, lung, heart, adrenal, skin, testis, and 
anterior pituitary (Andersen et al. 1993). A human homologue of the Brn-5 
protein has also been isolated from human muscle tissues (mPOU) (Wey et al. 
1994). Functionally, POU6F proteins are capable of influencing both 
transcriptional repression and activation. Transactivation experiments revealed 
that mPOU could act as a repressor of Oct2A mediated activation (Wey and 
Schafer 1996). EMB, a murine class 6 POU protein, interacts with other 
transcription factors, MEF2 and histone transacetylase p300, to regulate cardiac 
actin gene expression (Molinari et al. 2004). The ability of a transcription factor 
to function both as a repressor and activator was shown to be due to the 
interacting cis-element (Rao 2001). The structure of the transcription factor may 
change according to the DNA sequence it binds, and this structural change affects 
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its interaction with its transcription factor partners. Thus, this enables a single 
transcription factor to have both repressing and activating influences.  
With regards to the DNA-binding specificity of this class of POU proteins, 
although it binds to the classical octamer motif, it is also capable of interacting 
with other AT-rich octamer motifs (Andersen et al. 1993; Scholer 1991; Wey and 
Schafer 1996). In summary, POU6F proteins show expression patterns and DNA-
binding characteristics which are distinct and divergent from the other classes of 
POU proteins. Therefore, although POU transcription factors usually regulate 
genes involve in development processes, POUF6 members may regulate a distinct 
set of genes (Wey et al. 1994). 
 
Conclusion 
From the VERSE promoter characterization, the Sup cis-element itself may 
function as a supressor but it might work synergistically with Up2 cis-element to 
result in an overall up-regulatory influence on transcription. Also, as the trocarin 
D gene is present in all tissues of the snake, one of the mechanisms which 
determine its elevated and exclusive expression in the venom gland could be 
attributed to presence or availability of trans-factors which vary in different cell 
types. Therefore, the trans-factors that interact with the Sup cis-element should 
have (1) tissue-specific expression, (2) the ability to work cooperatively with 
other trans-factors, and (3) have the ability to influence transcription both 
negatively and positively. From the description above, POU6F transcription 
factors fit these criteria. In support, although the Sup cis-element 
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(TTGGACAGATACC) does not fit the classical octamer motif of the POU 
transcription factors, it has a high AT content (7 out of the 13 residues are either 
A or T) which POU6F members may be capable of binding to. The Sup cis-
element may present a new binding motif of POU6F transcription factors. Taking 
all the above into consideration, it is plausible that the Sup trans-factor belongs to 
the POU6F transcription factor family.  
 
The trocarin D regulatory network at the trans-factor level has only been 
partially elucidated and the identification of the other VERSE trans-factors (Up1 
and Up2) is important in order to complete the whole network. One immediate 
experiment would be to purify the trans-factors which interact with the Up1 and 
Up2 cis-elements by further optimizing the binding conditions of the oligos and 
the nuclear extracts during DNA-affinity chromatography. Another experiment 
that could be performed would be to use the Sup trans-factor (POU6F) as a pull-
down bait to isolate the trans-factor which interacts with the Up2 cis-element. 
This is possible because the VERSE characterization suggests that Sup and Up2 
cis-elements work synergistically and the trans-factors of Sup and Up2 may 
interact with each other.  
 
It must be noted that the above results which have identified POU6F 
trans-factor as the interacting Sup cis-element transcription factor are preliminary. 
Further experiments should be performed to confirm their interaction. (1) 
Supershift assays – During EMSA, the trans-factor will interact with the labeled 
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probe and retard its migration in the protein gel. If POU6F binds to the Sup oligo, 
the addition of the POU6F antibodies will bind to the POUF6/Sup-oligo complex 
and cause even more retardation. If this is observed, POU6F trans-factor can be 
concluded to interact with the Sup cis-element. (2) POU6F trans-factor can be 
recombinantly expressed. This recombinant protein can be tested if it interacts 
with the Sup oligo using EMSA.  
 
 The aim of this thesis is to understand the regulatory elements that are 
responsible for the elevated level and tissue-specific expression of trocarin D in 
snake venom gland cells. Therefore, it should be noted that one major limitation 
of these results is that it only confirms POU6F trans-factor binding to the Sup cis-
element in mammalian cell lines, particularly HEK293T cells. To conclude that 
POU6F trans-factor plays a role in the regulating trocarin D expression, its 
expression and interaction have to be confirmed within the snake venom gland 
cells. The expression of POU6F trans-factor within snake venom gland cells can 
be investigated by using the POU6F antibodies against nuclear extract of the 
snake venom gland cells. Interaction of the POU6F trans-factor with the Sup cis-
element can be investigated by using purified POU6F trans-factor from the 
nuclear extract of the snake venom gland cells to perform EMSA. 












Conclusion and future prospects 
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CONCLUSION 
Snake venom toxins have been documented to be related to body proteins 
which have been recruited for expression in the venom glands as toxins by gene 
duplication and accelerated evolution. This evolutionary relationship has been 
well-established by phylogenetic studies, and the gene organization determination 
of the snake venom toxins and their body protein counterparts. Our laboratory has 
extensively characterized two venom prothrombin activators, pseutarin C from 
Pseudonaja textilis and trocarin D from Tropidechis carinatus, each as 
representatives of the group C and D venom prothrombin activators. It was 
determined that these two venom toxins are structurally and functionally similar 
to mammalian blood coagulation factors. Pseutarin C is similar to the mammalian 
blood coagulation “FXa-FVa” complex and trocarin D is similar to the 
mammalian blood coagulation FXa. Structurally, these venom prothrombin 
activators have identical domain architecture and significant amino acid sequence 
similarity when compared to their mammalian counterparts. Functionally, these 
venom prothrombin activators activate prothrombin to thrombin to induce blood 
clotting by targeting the same cleavage sites as mammalian FXa. As snakes also 
require blood coagulation factors in their body, they should have parallel 
prothrombin activator system: one in the venom gland as a toxin and the other in 
the body as a haemostatic system. The presence of this parallel prothrombin 
activator system in snake was confirmed by determining the cDNA of blood 
coagulation FX from the liver of T. carinatus snake. Thereafter, trocarin D and its 
T. carinatus blood coagulation FX (TrFX) counterpart were chosen as 
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representatives to investigate if snake venom prothrombin activators and blood 
coagulation factors are evolutionarily related or two different groups of proteins 
with similar structures and functions.  
 
The gene organizations of trocarin D and TrFX revealed identical 
architectures (eight exons and seven introns) and the intron/exon boundaries were 
similar. The gene sequences showed high similarities, except for 
insertions/deletions in their promoter and intron 1 regions. Therefore, this 
suggests that trocarin D is evolutionarily related to TrFX and that trocarin D was 
recruited from the gene of TrFX into the venom gland for elevated and exclusive 
expression as toxins by gene duplication and accelerated evolution. The 
insertions/deletions segments identified in the promoter and intron 1 regions of 
the trocarin D gene were hypothesized to be responsible for its change in 
expression pattern. This thesis aimed to elucidate the molecular mechanisms 
behind the elevated and venom gland-exclusive expression of trocarin D by 
characterizing these segments for their regulatory cis-elements and corresponding 
trans-factors. 
 
Compared to TrFX, there is a 264 bp insertion in the trocarin D promoter. 
This insertion is postulated to play a major role in the recruitment of TrFX and is 
termed as the Venom Recruitment/Switch Element (VERSE). Bioinformatics 
analysis predicted TATA- , GATA- and Y-box cis-elements within the VERSE 
promoter. A similar 271 bp VERSE insertion is also present in the PCCS promoter 
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when it is compared against that of PFX. Hence, this VERSE promoter should 
play a major role in the recruitment of blood coagulation FX into the venom gland 
for expression. The trocarin D VERSE promoter was characterized for its 
regulatory cis-elements using luciferase assays in primary P. textilis snake venom 
gland cells and mammalian cell lines. The first observation was that VERSE is 
capable of driving luciferase expression and its up-regulatory effect is comparable 
to the full trocarin D promoter. Hence, this confirms that VERSE is the main 
segment responsible for the trocarin D elevated expression in the venom gland. 
The initial cis-element characterization confirms the presence of TATA-, GATA- 
and Y-boxes. The luciferase assay results from the primary P. textilis snake 
venom gland cells were similar to those of the mammalian cell lines, HepG2, 
HEK293T and CHOK1. For the first time, this suggests that mammalian cell lines 
are reasonable substitutes for snake venom gland cells. It is important to find a 
substitute cell model for snake venom gland cells as completing all the 
characterization studies would require many venom glands to be obtained by 
sacrificing of many snakes. This would be costly and, most importantly, unethical. 
Subsequent VERSE characterization was performed using mammalian cell lines. 
Serial deletion assays identified three other novel cis-elements (Sup, Up1 and 
Up2). Characterization by site-directed mutagenesis studies indicates that Up1 
and Up2 have up-regulatory effects, and while Sup by itself has suppressing 
effects, Sup works synergistically with Up2 to up-regulate the expression of 
trocarin D. Besides luciferase assays, 5’ RACE was performed to characterize the 
roles of the two TATA-like boxes within VERSE. It was determined that TLB2 is 
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the main TATA box which directs the position of the transcription start site. This 
completes the full characterization of VERSE for its regulatory cis-elements. To 
our knowledge, this is the first time that a snake venom toxin promoter has been 
fully characterized and understood for how its elevated expression levels are 
regulated in terms of its cis-elements. 
 
As trocarin D has a level of expression which is ~30 times higher 
compared to TrFX, VERSE was further investigated if it has any potential towards 
being used as a promoter for recombinant protein expression. The VERSE 
promoter was compared against the commonly used Cytomegalovirus (CMV) 
viral promoter to investigate its promoter activity. It was found that the VERSE 
up-regulatory effect was comparable to that of the CMV promoter in HEK293T 
cell lines. Also, the VERSE minimal core promoter (VERSE MCP) was identified 
to be -125 to +18 bp (143 bp). This is about half the size of VERSE (264 bp) and 
less than one-fifth the size of the commonly used CMV viral promoter (741 bp). 
Therefore, these results indicate potential for development of a small potent 
promoter for recombinant protein expression in mammalian cell lines, especially 
HEK293T. The VERSE MCP can be further modified to increase its promoter 
potency and be tested for its capability to drive recombinant protein expression in 
mammalian cell lines. Also, other cell lines can also be explored to investigate if 
VERSE has a more efficient promoter activity in those cells. 
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As VERSE was still able to drive expression in all tested mammalian cell 
lines, the silencer cis-element which functions to “turn off” trocarin D expression 
in other non-venom gland cells was hypothesized to reside within the trocarin D 
intron 1 insertion/deletion segments. Compared to TrFX, there are three insertions 
and two deletions in the trocarin D intron 1 region. These insertions/deletions are 
characterized using luciferase assays in mammalian cell lines. A scaffold matrix 
attachment region which was previously predicted within insertion 3 segment 
using bioinformatics tools was found to be nonfunctional. From the insertion 2 
segment (1975 bp), there were several silencer cis-elements found within Ins2.2 
(687 bp) and the most potent element was identified to reside within Ins2.2.4  
(193 bp). Further bioinformatics analysis pinpointed a 26 bp segment within 
Ins2.2.4 as a potential silencer cis-element which probably functions to “turn off” 
trocarin D expression in other tissues. As this silencer cis-element was also found 
to be present in the intron 1 region of PCCS and other snake venom toxins, it 
could be a key regulatory element in determining the venom gland-specific 
expression of snake toxins. To our knowledge, this is the first report of such a 
tissue-specific silencer cis-element found in snake venom toxins. It also highlights 
the intron 1 region of snake venom toxins as the regulator for tissue-specific 
expression. As more snake venom toxin genes are being sequenced, it can be 
investigated if this and other silencer cis-elements exist in their intron 1 regions.  
 
Despite the full regulatory cis-element characterization of the VERSE 
promoter and trocarin D intron 1 insertion/deletion regions, it only reveals half the 
Chapter 5 - Conclusion and future prospects 
140 
trocarin D regulatory network. The cis-elements are only “sign-boards” that 
attract the trans-factors which are the actual “effectors” that determine 
transcription. Hence, focus shifted towards purifying and identifying the 
corresponding trans-factors which might play a role in the elevated and exclusive 
expression of trocarin D. As most of the VERSE cis-elements (TATA-, GATA- 
and Y-box) have already been well-characterized, the trans-factors which 
interacted with the novel VERSE cis-elements (Sup, Up1 and Up2) were targeted. 
Due to the low concentrations and non-specific bindings of the Up1 and Up2 cis-
elements, only the trans-factor which interacts with the Sup cis-element was 
purified and identified. It was identified as a class 6 POU transcription factor. 
Although Sup cis-element does not match any of the previously identified POU6F 
binding motifs, it satisfies the condition of being AT rich. Therefore, the Sup  
cis-element may present a new POU6F binding motif. However, with the 
identification of only the Sup trans-factor, it is difficult to piece together the 
trocarin D regulatory network. Therefore, the purification of the other  
trans-factors is necessary. As mentioned in the discussion of chapter 4, the  
trans-factors which interact with the Up1 and Up2 cis-elements can be purified by 
either optimizing the DNA-binding chromatography conditions or using the Sup 
trans-factor as a pull-down. With the complete identification of all the various 
VERSE trans-factors, structural studies can be performed to investigate how these 
VERSE trans-factors interact together to influence the overall trocarin D 
transcription initiation and efficiency. Once this information comes together, we 
can then fully elucidate the trocarin D regulatory network. 
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The regulatory cis-elements of the trocarin D gene have been fully 
characterized and some of the interacting trans-factors have been identified. 
These results help to elucidate the mechanisms in which the trocarin D gene is 
regulated for its elevated and exclusive expression in the venom gland. All the 
VERSE and silencer cis-elements identified are also present within the PCCS gene, 
encoding the catalytic subunit of a group C venom prothrombin activator. 
Therefore, it is reasonable to extend the characterization and our understanding of 




 While the significance of the results with regards to understanding snake 
venom prothrombin activators are intriguing and exciting, the limitations of this 
study must be considered. One limitation is the lack of available Tropidechis 
carinatus snake venom gland cell lines and mammalian cell lines had to be used 
as a substitute model system for the characterization studies. Therefore, we can 
only use the results derived from the mammalian cell lines as a reference as to 
how the VERSE and silencer cis-elements function towards regulating the 
expression of trocarin D in the snake venom gland cells. However, as it has been 
demonstrated that mammalian cell lines are reasonable substitutes for venom 
glands, the identification of the VERSE regulatory cis-elements is still valid and 
their functions derived from the characterization studies are a good reference of 
its actual physiological roles in the snake venom gland. As a confirmation, future 
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functional characterization of these VERSE regulatory cis-elements can be 
validated within its native snake venom gland cell environment. The number of 
snakes that is needed to be sacrificed can be significantly reduced by using the 
mammalian cell line VERSE characterization as a guide to identify only the 
important constructs which need to be assayed in the primary snake venom gland 
cells. 
 
Another limitation of this study is that the trans-factor which interacts 
with the Sup cis-element was purified from HEK293T cells. It is not known if 
such a trans-factor exists within the snake genome. If it does not exist, the 
identification of the class 6 POU transcription factor would be irrelevant. 
However, its existence can be easily confirmed by using antibodies which specific 
to class 6 POU transcription factor against nuclear extracts from T. carinatus 
snake venom gland cells. 
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IMPLICATIONS AND FUTURE DIRECTIONS 
 
Fundamental Research  
 The identification and characterization of the insertions/deletions 
segments in the trocarin D promoter and intron 1 regions shed light on the 
evolutionary developments of snake venom prothrombin activators. Other groups 
of snake venom toxins, e.g. three finger toxins, are also recruited from the genes 
of body proteins. Therefore, their recruitment process should involve regulatory 
cis-elements which elevate and cause their expression to be exclusive in the 
venom glands. Hence, are their cis-elements similar to those trocarin D VERSE 
and silencer cis-elements? If not, it would be interesting to identify and 
characterize those cis-elements. Besides recruitment, venom toxins have isoforms 
within the same tissue which have also arisen due to gene duplications and 
accelerated evolution. These isoforms have different functions and expression 
levels. The difference in functions arises due to mutations in the coding regions 
which affect the amino acid sequence. On the other hand, as these isoforms exist 
within the same tissue and the available trans-factors are the same, differences in 
regulatory regions are responsible for the changes in expression levels. It would 
be interesting to compare the gene organizations of these isoforms and identify 
regions of differences in the regulatory regions. Almost nothing is known about 
the snake genome. Therefore, a compilation of the regulatory elements identified 
will enable us to understand the snake genome better. 
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Application Perspectives 
A lot of research has been primarily focused on characterizing, isolating 
and modifying snake venom toxins for therapeutic purposes. This research 
direction has been proven to be very successful as seen from the many 
pharmaceutical products have been developed from snake venom toxins. However, 
not much focus has been given towards research of snake venom toxins at the 
genome level. The research in this area has so far has mostly been in the domain 
of basic research. As seen from the results of this thesis, there can be many 
potential applications which can be derived from understanding how these snake 
venom toxin genes are regulated. Therefore, we firmly believe that with better 
understanding of their gene regulation as contributed by this thesis, new avenues 
can be open up in this direction for application research.  
 
Snake venom toxins have elevated and tissue-specific expression patterns. 
These are two characteristics which have many potential applications. As shown 
by the comparable up-regulatory potency of VERSE against the commonly used 
Cytomegalovirus promoter and together with the results which indicate that 
VERSE can be further reduced to one-third its size. This indicates a potential 
promoter which could be further developed for the driving recombinant protein 
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Recombinant expression 
There are several expression systems, mainly bacteria, yeast, insect cell 
lines and mammalian cell lines, available for the recombinant expression of 
proteins. Each system has its own advantages and disadvantages. The 
recombinant pharmaceutical industry is in the business of treating human patients. 
Hence, the industry prefers to use mammalian cell lines as it is a homologous 
system. The mammalian cell line system has the most sophisticated expression 
system which is able to perform complicated post-translational modification. 
Hence, the chances of the patient’s body rejecting the recombinant protein are 
lower. However, the mammalian cell line expression system has its disadvantages 
compared to the other expression systems. A few to list are slower cell growth, 
less efficient rate of transfection, and most importantly, low yield of protein 
expressed. This results in the high cost of production which usually burdens the 
patient in terms of treatment cost. However, these limitations can be overcomes if 
the level of expression can be elevated. The trocarin D VERSE promoter provides 
a potential effective alternative which can be used to elevate expression in 
mammalian cell lines. As recombinant proteins make up a significant percentage 
of the drug market, there is a significant commercial benefit in the development of 
better promoters to increase the yields of recombinant protein expression in 
mammalian cell line systems. 
 
One group of recombinant proteins which could be benefit from using 
VERSE as a promoter is the blood coagulation factors. VERSE is a promoter that 
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has been shown to elevate the expression of trocarin D which is a structural and 
functional prothrombin activator homologue of blood coagulation FX. Hence, it 
can be used as a homologous promoter to drive the expression of blood 
coagulation FX and possibly the other blood coagulation factor members such as 
FIX, FVII and FVIII. These are blood coagulation factors that are being expressed 
recombinantly and infused into the bodies of patients who suffer from hemophilia 
which is a hereditary bleeding disorder. The current sources of these blood 
coagulation factors are either derived directly from human plasma or by 
recombinant expression. However, due to the low abundance of blood coagulation 
factors in the plasma and the health safety concerns, recombinant expression is 
the primary source of these proteins. As the cost of recombinant expression is 
high, this treatment is expensive. It is quoted that ADVATE, the recombinant 
FVIII from Baxter, costs US$12, 500 per dose and a FVIII deficient hemophilic 
patient will require several doses per week. Therefore, there is significant health 
and patient cost advantages if the expression of these blood coagulation factors 




Gene therapy is an upcoming treatment for various genetic disorders. In 
these disorders, the gene of interest is usually a defective non-functional mutant 
allele (Briat and Vassaux 2006; Fine 2010; Iijima et al. 2010; Kong et al. 2010). 
During gene therapy, the targeted cells are transfected with a viral carrier which 
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consists of the functional gene with a suitable promoter. Upon transfection, the 
functional gene is integrated into the genome of the targeted cell. The promoter 
then drives the expression of the functional gene; hence, correcting the genetic 
disorder. Most viral constructs employs the use of a single or chimeric promoter 
which is usually several kb in length (Balague et al. 2000; Chao et al. 2000). The 
VERSE promoter and tissue-specific silencer cis-elements are potential regulatory 
elements that can be incorporated in gene therapy. VERSE provides a shorter but 
potent promoter. This could increase the efficiency of the gene therapy treatment. 
Also, if transfection of the viral carrier occurs in neighboring cells which are not 
targeted, incorporation of the trocarin D  
tissue-specific silencer cis-element can prevent the unwanted expression of the 
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List of Primers Used for Making VERSE Constructs 
Primers Nucleotide sequences 
VERSE Forward  5' TCG GGTACC TGTACTTGTTTGCATACTCG 3' 
VERSE Reverse 5’ AGC GCTAGC GGTGCCTATCGATG 3’ 
mGATA 5' GCTTAACGATTGGTACATTACAACAGTTC 3' 
mYbox 5’ GTTTTAAATAAATGCCATCTGTTGCGA 
GCCGCGAGC 3’ 
mTLB2 5’ CCGCTATCCAAGGGGCTGCCGC 3’ 
mTLB3 5' GGAGTTTTATTTACATGCCATTGGTTGC 3' 
mSup 5’ CCTATTAGACGGACACCATCGC 3’   
mUp1 5’ CAGGTCTGATTAGCCGC 3’ 
mUp2 5’ TAACACTGAATCCCTATTGG 3’ 
Universal Primer 5’ CTAATACGACTCACTATAGGGC 3’  
Nested Universal Primer 5’ AAGCAGTGGTATCAACGCAGAGT 3’ 
5'GSP1 5' CACAAGCGGTGCGGTGCGGTAGGGCTACG 
3' 
5'GSP2 5’ GTCGGTCTTGCTATCCATGATGATGATC 3’ 
  
Constructs Primers used in PCR reactions 
VERSE VERSE Forward and VERSE Reverse 
mGATA VERSE Forward, mGATA and VERSE Reverse 
mYbox VERSE Forward, mYbox and VERSE Reverse 
mTLB2 VERSE Forward, mTLB1and VERSE Reverse 
mTLB3 VERSE Forward, mTLB2 and VERSE Reverse 
mSup VERSE Forward, mSup and VERSE Reverse 
mUp1 VERSE Forward, mUp1 and VERSE Reverse 
mUp2 VERSE Forward, mUp2 and VERSE Reverse 
 
 
